• Abdulahad WH, Stegeman CA, Kallenberg CG. Review article: the role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology (Carlton) 14: 26-32 (2009).

• Abe H, Tsuboi N, Yukawa S, Tsuji S, Hayashi H, Yukawa N, Takanashi H, Tahara K, Tonozuka N, Hayashi T. Thrombotic thrombocytopenic purpura complicating Sjogren's syndrome with crescentic glomerulonephritis and membranous nephritis. Mod. Rheumatol. 14: 174-178 (2004).

• Abe J, Ueha S, Suzuki J, Tokano Y, Matsushima K, Ishikawa S. Increased Foxp3+ CD4+ regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am. J. Pathol. 173: 1682-1692 (2008). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Adams DD. A study of the pathogenesis of rheumatic fever, glomerulonephritis and other autoimmune diseases triggered by infection. Clin. Exp. Immunol. 5: 105-115 (1969). *

• Agharazii M, Marcotte J, Boucher D, Noel R, Lebel M. Chronic interstitial nephritis due to 5-aminosalicylic acid. Am. J. Nephrol. 19: 373-376 (1999).

• Agrawal N, Chiang LK, Rifkin IR. Lupus nephritis. Semin. Nephrol. 26: 95-104 (2006).

• Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 58: 335-338 (2001). *

• Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF. Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J. Rheumatol. 30: 1770-1774 (2003).

• Ahn SY, Ingulli E. Acute poststreptococcal glomerulonephritis: an update. Curr. Opin. Pediatr. 20: 157-162 (2008).

• Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851-855 (2006). *

• Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 57: 837-844 (2007). *

• Al-Awadhi AM, Haider MZ, Sharma PN, Hasan EA, Botaiban F, Al-Herz A, Nahar I, Al-Enezi H, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in Kuwaiti patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 25: 437-442 (2007).

• Ala-Mello S, Kaariainen H, Koskimies O. Nephronophthisis and ulcerative colitis in siblings: a new association. Pediatr. Nephrol. 16: 507-509 (2001).

• Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA, Jennette JC, Falk RJ. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int. 72: 853-864 (2007).

• Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr. Opin. Rheumatol. 20: 538-544 (2008).

• Allam R, Pawar RD, Kulkarni OP, Hornung V, Hartmann G, Segerer S, Akira S, Endres S, Anders HJ. Viral 5'-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur. J. Immunol. 38: 3487-3498 (2008). *

• Almroth G, Axelsson T, Mussener E, Grodzinsky E, Midhagen G, Olcen P. Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups. J. Med. Sci. 111: 339-352 (2006). *

• Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr. Opin. Nephrol. Hypertens. 17: 243-249 (2008).

• Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC. Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association? J. Rheumatol. 33: 2351-2353 (2006).

• Amital H, Heilweil M, Ulmansky R, Szafer F, Bar-Tana R, Morel L, Foster MH, Mostoslavsky G, Eilat D, Pizov G, Naparstek Y. Treatment with a laminin-derived peptide suppresses lupus nephritis. J. Immunol. 175: 5516-5523 (2005). *

• Anam K, Amare M, Naik S, Szabo K, Davis T. Severe tissue trauma triggers the autoimmune state systemic lupus erythematosus in the MRL/++ lupus-prone mouse. Lupus 18: 318-331 (2009).

• Anaya S, Sanchez de la Nieta MD, Blanco J, Rivera F. Lupus nephritis and hypothyroidism. Nefrologia 27: 87-88 (2007).

• Anders HJ, Krug A, Pawar RD. Molecular mimicry in innate immunity? The viral RNA recognition receptor TLR7 accelerates murine lupus. Eur. J. Immunol. 38: 1795-1799 (2008). *

• Anders HJ, Schlondorff D. Toll-like receptors: emerging concepts in kidney disease. Curr. Opin. Nephrol. Hypertens. 16: 177-183 (2007).

• Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. 19: 859-878 (2005).

• Antar M, Lamarche J, Peguero A, Reiss A, Cole S. A case of selective immunoglobulin M deficiency and autoimmune glomerulonephritis. Clin. Exp. Nephrol. 12: 300-304 (2008).

• Aoki A, Sato K, Itabashi M, Takei T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. A case of Mikulicz's disease complicated with severe interstitial nephritis associated with IgG4. Clin. Exp. Nephrol. Jan 14 [Epub ahead of print] (2009).

• Apenteng T, Kaplan B, Meyers K. Renal outcomes in children with lupus and a family history of autoimmune disease. Lupus 15: 65-70 (2006).

• Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 69: 1939-1944 (2006). *

• Ara J, Mirapeix E, Rodriguez R, Pascual J, Alvarez L, Darnell A. Usefulness of anti-neutrophil cytoplasmic antibodies, anti-proteinase 3 and anti-myeloperoxidase in management of small vessel vasculitis. Med. Clin. (Barc.) 111: 536-568 (1998).

• Ardiles LG, Valderrama G, Moya P, Mezzano SA. Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Clin. Nephrol. 47: 1-5 (1997).

• Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 27: 337-343 (1993).

• Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr. Nephrol. 19: 550-553 (2004). *

• Arends J, Wu J, Borillo J, Troung L, Zhou C, Vigneswaran N, Lou YH. T cell epitope mimicry in antiglomerular basement membrane disease. J. Immunol. 176: 1252-1258 (2006). *

• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169 (2004). *

• Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res. Ther. 10: 202 (2008). *

• Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin. Drug Saf. 7: 411-419 (2008).

• Arnett FC. Genetic studies of human lupus in families. Int. Rev. Immunol. 19: 297-317 (2000).

• Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin. Rheumatol. 27: 261-264 (2008). *

• Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J. Immunol. 180: 1231-1238 (2008). *

• Auer IO. Immunologic aspects of chronic inflammatory intestinal diseases. Klin. Padiatr. 195: 337-341 (1983).

• Auwardt RB, Mudge SJ, Chen CG, Power DA. Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells. J. Am. Soc. Nephrol. 9: 1620-1628 (1998).

• Awadallah S, Hamad M. A study of haptoglobin phenotypes in patients with chronic renal failure. Ann. Clin. Biochem. 40: 680-683 (2003).

• Ayala de la Cruz Mdel C, Gonzalez Diaz R, Lopez Lara ND. Wegener's granulomatosis. Report of a pediatric case and review of the literature. Rev. Alerg. Mex. 50: 71-75 (2003).

• Badakere SS, Pradhan VD, Almeida AF, Pawar AR. Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3. J. Fluoresc. 14: 459-463 (2004). *

• Baig S, Alamgir M. The extrahepatic manifestations of hepatitis B virus. J. Coll. Physicians Surg. Pak. 18: 451-457 (2008).

• Baillat D, Leprivier G, Regnier D, Vintonenko N, Begue A, Stehelin D, Aumercier M. Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter. Oncogene 25: 5764-5776 (2006). *

• Baker KP. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun. Rev. 3: 368-375 (2004).

• Bakrac M, Bonaci B, Krstic M, Simic S, Colovic M. A rare case of enteropathy-associated T-cell lymphoma presenting as acute renal failure. World J. Gastroenterol. 12: 2301-2304 (2006). *

• Bantis C, Heering PJ, Aker S, Siekierka M, Kuhr N, Grabensee B, Ivens K. Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis. Am. J. Nephrol. 26: 12-15 (2006).

• Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur. J. Immunol. 35: 2496-2506 (2005). *

• Bao L, Quigg RJ. Complement in lupus nephritis: the good, the bad, and the unknown. Semin. Nephrol. 27: 69-80 (2007).

• Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs 11: 111-115 (2008).

• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int. J. Exp. Pathol. 85: 321-334 (2004). *

• Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun. Rev. 4: 565-570 (2005).

• Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus 15: 94-101 (2006).

• Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Ruckle T, Schwarz MK, Rodriguez S, Martinez-A C, Balomenos D, Rommel C, Carrera AC. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11: 933-935 (2005). *

• Bargman JM. Why are rheumatologists treating lupus nephritis? Nat. Clin. Pract. Nephrol. 3: 296-297 (2007).

• Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, Batalov S, Liu Y, Warmuth M, Wiltshire T, Cooke MP, Sauer K. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33: 43-52 (2009). *

• Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J. Soc. Integr. Oncol. 5: 92-105 (2007).

• Baskin E, Agras PI, Menekse N, Ozdemir H, Cengiz N. Full-house nephropathy in a patient with negative serology for lupus. Rheumatol. Int. 27: 281-284 (2007). *

• Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vila LM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 46: 683-689 (2007). *

• Bates JS, Lessard CJ, Leon JM, Nguyen T, Battiest LJ, Rodgers J, Kaufman KM, James JA, Gilkeson GS, Kelly JA, Humphrey MB, Harley JB, Gray-McGuire C, Moser KL, Gaffney PM. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. Apr 23 [Epub ahead of print] (2009).

• Baudino L, Azeredo da Silveira S, Nakata M, Izui S. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin. Immunopathol. 28: 175-184 (2006). *

• Bazilio AP, Viana VS, Toledo R, Woronik V, Bonfa E, Monteiro RC. Fc gamma RIIa polymorphism: a susceptibility factor for immune complex-mediated lupus nephritis in Brazilian patients. Nephrol. Dial. Transplant. 19: 1427-1431 (2004). *

• Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24: 2283-2289 (2006). *

• Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, Nossent JC. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res. Ther. 8: R162 (2006). *

• Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15: 570-576 (2006).

• Bee PC, Gan GG, Sangkar VJ, Haris AR. Nephrotic syndrome in a patient with relapsed of chronic myeloid leukemia after peripheral blood stem cell transplantation. Med. J. Malaysia 63: 71-72 (2008).

• Behrens R, Ruder H. Chronic inflammatory intestinal disease and nephritis. Klin. Padiatr. 204: 61-64 (1992).

• Belmont HM. Treatment of ANCA-associated systemic vasculitis. Bull. Hosp. Jt. Dis. 64: 60-66 (2006). *

• Ben M'rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y, Guesmi M, Rollot F, Dehoux M, Guillevin L, Moachon L. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 88: 131-140 (2009).

• Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 56: 1569-1578 (2007). *

• Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J. Am. Soc. Nephrol. 17: 1624-1632 (2006). *

• Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177: 7287-7295 (2006). *

• Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 428-434 (2002).

• Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, Kardassis D, Mamalaki C, Boumpas DT. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 60: 207-218 (2009). *

• Bigazzi PE. Autoimmunity and heavy metals. Lupus 3: 449-453 (1994).

• Bindi D, Johanet C, Gilson B, Evon P, Aymard B, Gay G. Membranous glomerulonephritis associated with primary biliary cirrhosis: a pathogenic role of anti-M2 antibodies? Gastroenterol. Clin. Biol. 17: 142-143 (1993).

• Birchard KR, Brown MA, Hyslop WB, Firat Z, Semelka RC. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am. J. Roentgenol. 184: 452-458 (2005). *

• Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int. 57: 129-136 (2000). *

• Birmingham DJ, Irshaid F, Gavit KF, Nagaraja HN, Yu CY, Rovin BH, Hebert LA. A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding. Mol. Immunol. 44: 3510-3516 (2007). *

• Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, Hackshaw KV, Yu CY, Malarkey WB, Hebert LA. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele. Arthritis Rheum. 54: 3291-3299 (2006). *

• Bishof NA, Welch TR, Beischel LS, Carson D, Donnelly PA. DP polymorphism in HLA-A1,-B8,-DR3 extended haplotypes associated with membranoproliferative glomerulonephritis and systemic lupus erythematosus. Pediatr. Nephrol. 7: 243-246 (1993).

• Bissuel F, Bizollon T, Dijoud F, Bouletreau P, Cordier JF, Chazot C, Gouillat C, Trepo C. Pulmonary hemorrhage and glomerulonephritis in primary biliary cirrhosis. Hepatology 16: 1357-1361 (1992).

• Biyikli NK, Gokce I, Cakalagoglu F, Arbak S, Alpay H. The co-existence of membranoproliferative glomerulonephritis type 1 and coeliac disease: a case report. Pediatr. Nephrol. Jan 31 [Epub ahead of print] (2009).

• Blenman KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, Croker BP, Morel L. IL-10 regulation of lupus in the NZM2410 murine model. Lab. Invest. 86: 1136-1148 (2006). *

• Bolton WK, Chen L, Hellmark T, Fox J, Wieslander J. Molecular mapping of the Goodpasture's epitope for glomerulonephritis. Trans. Am. Clin. Climatol. Assoc. 116: 229-236 (2005). *

• Bolton WK, Chen L, Hellmark T, Wieslander J, Fox JW. Epitope spreading and autoimmune glomerulonephritis in rats induced by a T cell epitope of Goodpasture's antigen. J. Am. Soc. Nephrol. 16: 2657-2666 (2005). *

• Borza DB, Bondar O, Colon S, Todd P, Sado Y, Neilson EG, Hudson BG. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis. J. Biol. Chem. 280: 27147-27154 (2005). *

• Borza DB, Chedid MF, Colon S, Lager DJ, Leung N, Fervenza FC. Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am. J. Kidney Dis. 45: 397-406 (2005).

• Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 368: 404-418 (2006). *

• Bosque Lopez MJ, Garrido Duran C, Ginard Vicens D, Munar Vila MA, Vanrell Garau M, Marino Mendez Z, Gaya Cantallops J. Severe tubulo-interstitial nephritis secondary to 5-ASA. Gastroenterol. Hepatol. 32: 29-31 (2009).

• Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, Oates J, Gilkeson G. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J. Rheumatol. 34: 2028-2034 (2007).

• Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat. Clin. Pract. Rheumatol. 1: 22-30 (2005). *

• Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin. Immunol. Immunopathol. 70: 145-151 (1994).

• Brambila-Tapia AJ, Davalos-Rodriguez IP. Fcgamma receptors polymorphisms and systemic lupus erythematosus. Rev. Invest. Clin. 61: 66-72 (2009).

• Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, Andrassy K. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand. J. Rheumatol. 36: 291-298 (2007). *

• Breda L, Nozzi M, De Sanctis S, Chiarelli F. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update. Semin. Arthritis Rheum. Feb 24 [Epub ahead of print] (2009). *

• Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, Frank MM. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J. Allergy Clin. Immunol. 77: 749-757 (1986).

• Bridoux F, Kyndt X, Abou-Ayache R, Mougenot B, Baillet S, Bauwens M, Lemaitre V, Goujon JM, Touchard G, Vanhille P. Proximal tubular dysfunction in primary Sjogren's syndrome: a clinicopathological study of 2 cases. Clin. Nephrol. 61: 434-439 (2004).

• Brouwer E, Tervaert JW, Horst G, Huitema MG, van der Giessen M, Limburg PC, Kallenberg CG. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83: 379-386 (1991). *

• Brown HJ, Lock HR, Sacks SH, Robson MG. TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis. J. Immunol. 177: 1925-1931 (2006). *

• Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG. Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J. Am. Soc. Nephrol. 18: 1732-1739 (2007). *

• Brown JM, Pfau JC, Pershouse MA, Holian A. Silica, apoptosis, and autoimmunity. J. Immunotoxicol. 1: 177-187 (2005).

• Brown JM, Schwanke CM, Pershouse MA, Pfau JC, Holian A. Effects of rottlerin on silica-exacerbated systemic autoimmune disease in New Zealand mixed mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L990-L998 (2005). *

• Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, VON Feldt JM. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J. Rheumatol. 34: 740-746 (2007).

• Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3388-3394 (2008). *

• Brownlee AA, Lockwood CM. Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI). Clin. Exp. Immunol. 117: 183-189 (1999). *

• Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis - a critical approach. Semin. Arthritis Rheum. 36: 224-237 (2007). *

• Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl. Res. 150: 101-105 (2007). *

• Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun. Rev. 1: 321-328 (2002).

• Burnevich EZ, Lopatkina TN. System manifestations of primary biliary cirrhosis. Klin. Med. (Mosk.) 84: 42-46 (2006).

• Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F(1) mice. Genes Immun. 9: 137-152 (2008). *

• Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev. 4: 542-548 (2005).

• Calvino J, Romero R, Pintos E, Losada E, Novoa D, Guimil D, Mardaras J, Sanchez-Guisande D. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin. Nephrol. 49: 265-267 (1998).

• Calvo Romero JM, Romero Requena J, Arevalo Lorido JC, Ramos Salado JL, Doblare Castellano E, Vargas Perez ML, Bureo Dacal P, Perez Miranda M. Antineutrophil cytoplasmic antibodies (ANCA): clinico-pathologic correlations in a series of 82 cases. An. Med. Interna 19: 7-10 (2002).

• Cammelli D. Extra-articular manifestations of seronegative spondyloarthritis. Recenti Prog. Med. 97: 280-289 (2006).

• Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Front. Biosci. 9: 2273-2284 (2004).

• Carlucci F, Cortes-Hernandez J, Fossati-Jimack L, Bygrave AE, Walport MJ, Vyse TJ, Cook HT, Botto M. Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 loci when expressed on C57BL/6 mice. J. Immunol. 178: 2352-2360 (2007). *

• Carrion F, Figueroa F, Martinez ME, Massardo L, Perez T, Foster C, Mancilla C, Neira O, Guzman L, Valenzuela V, Urrutia R, Carmona S, Figueroa M, Lubiano A, Wainstein E. Study of polymorphism of Fc gamma IIa receptors in Chilean patients with systemic lupus erythematosus. Rev. Med. Chil. 131: 11-18 (2003).

• Casella G, Perego D, Baldini V, Monti C, Crippa S, Buda CA. A rare association between ulcerative colitis (UC), celiac disease (CD), membranous glomerulonephritis, leg venous thrombosis, and heterozygosity for factor V Leiden. J. Gastroenterol. 37: 761-762 (2002). *

• Castellano G. Lupus nephritis: a matter of tolerance. G. Ital. Nefrol. 24: 186 (2007).

• Celic D, Ilic T, Durdevic-Mirkovic T, Mitic I, Milic B, Curic S. Therapy of lupus nephritis with mycophenolate mofetil. Med. Pregl. 61: 270-273 (2008).

• Celic D, Ilic T, Durdevic-Mirkovic T, Mitic I, Milic B, Curic S. Therapy of lupus nephritis with mycophenolate mofetil. Med. Pregl. 60 Suppl. 2: 124-127 (2007).

• Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC. Intra-renal cytokine gene expression in lupus nephritis. Ann. Rheum. Dis. 66: 886-892 (2007). *

• Chan TM. Lupus nephritis: induction therapy. Lupus 14 Suppl. 1: s27-s32 (2005).

• Chan TM. Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. Arthritis Rheum. 56: 702-704 (2007). *

• Chan TM. Histological reclassification of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 14: 561-566 (2005).

• Chan YC, Tay YK, Ng SK. Allopurinol hypersensitivity syndrome and acute myocardial infarction - two case reports. Ann. Acad. Med. Singapore 31: 231-233 (2002). *

• Chandran V, Upadhyaya SK, Haroon N, Aggarwal A, Misra R. Lack of clinical association with antibodies to ribosomal p proteins in Indian patients with systemic lupus erythematosus. J. Rheumatol. 33: 1987-1989 (2006).

• Chang HK. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J. Korean Med. Sci. 20: 883-885 (2005). *

• Chang JM, Lee YR, Hung LM, Liu SY, Kuo MT, Wen WC, Chen P. An extract of Antrodia camphorata mycelia attenuates the progression of nephritis in systemic lupus erythematosus-prone NZB/W F1 mice. Evid. Based Complement. Alternat. Med. Sep 2 [Epub ahead of print] (2008).

• Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann. Pharmacother. 39: 1552-1556 (2005).

• Charonis A, Sideraki V, Kaltezioti V, Alberti A, Vlahakos D, Wu K, Tsilibary E. Basement membrane peptides: functional considerations and biomedical applications in autoimmunity. Curr. Med. Chem. 12: 1495-1502 (2005).

• Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, Arlet G, Hertig A, Rondeau E, Vandewalle A. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J. Exp. Med. 204: 2837-2852 (2007). *

• Cheema SR, Arif F, Charney D, Meisels IS, Cheema SS. IgA-dominant glomerulonephritis associated with hepatitis A. Clin. Nephrol. 62: 138-143 (2004).

• Chen D, Hsieh C, Chen K, Chen Y, Lin F, Lan J. Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis. Lupus 18: 29-37 (2009).

• Chen M, Aosai F, Norose K, Mun HS, Ishikura H, Hirose S, Piao LX, Fang H, Yano A. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice. Int. Immunol. 16: 937-946 (2004). *

• Chen M, Wang YY, Zhao MH, Zhang YK, Wang HY. Autoantibodies against glomerular mesangial cells and their target antigens in lupus nephritis. Ren. Fail. 27: 507-513 (2005).

• Chen M, Yu F, Zhang Y, Zhao MH. An analysis of multi-system involvement and renal pathology of anti-neutrophil cytoplasmic autoantibodies-related vasculitis. Zhonghua Nei Ke Za Zhi 44: 828-831 (2005).

• Chen M, Zhao M, Zhang Y, Wang H. Antigens of antineutrophil cytoplasmic autoantibodies in recognizing a novel neutrophil granule antigen in lupus nephritis and its association with photosensitivity and oral ulceration. Zhonghua Nei Ke Za Zhi 41: 766-768 (2002).

• Chen Y, Yang C, Xie Z, Zou L, Ruan Z, Zhang X, Tang Y, Fei L, Jia Z, Wu Y. Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells. Kidney Int. 70: 2092-2099 (2006). *

• Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang C, Jia Z, Wu Y. Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol. Immunol. 46: 375-383 (2009). *

• Chen YC, Kuo MC, Chen HC, Lai YH, Hwang SJ. HCV infection complicated with nephrotic syndrome, immune complex crescentic glomerulonephritis and acute renal failure: a case report. Kaohsiung J. Med. Sci. 21: 470-474 (2005).

• Cheng Y, Zhang J, Wang D, Li F, Zhang Y, Yuan F. Immunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis. Int. Immunopharmacol. 9: 894-899 (2009).

• Chiba K. A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720). Yakugaku Zasshi 129: 655-665 (2009).

• Chien JW, Chen WL, Tsui YG, Lee MC, Lin AY, Lin CY. Daily urinary interleukin-11 excretion correlated with proteinuria in IgA nephropathy and lupus nephritis. Pediatr. Nephrol. 21: 490-496 (2006). *

• Chikazawa H, Nishiya K, Matsumori A, Hashimoto K. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J. Clin. Immunol. 20: 279-286 (2000). *

• Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J. Rheumatol. 28: 1584-1590 (2001).

• Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of pristane-induced lupus. Rheumatology (Oxford) 46: 1405-1410 (2007). *

• Chowdhry IA, Kowal C, Hardin J, Zhou Z, Diamond B. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum. 52: 2403-2410 (2005). *

• Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202: 321-331 (2005). *

• Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428 (2006). *

• Chu ZT, Tsuchiya N, Kyogoku C, Ohashi J, Qian YP, Xu SB, Mao CZ, Chu JY, Tokunaga K. Association of Fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. Tissue Antigens 63: 21-27 (2004). *

• Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27: 461-466 (2007). *

• Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 36: 653-660 (1989).

• Colmegna I, Maldonado-Cocco JA. Polyarteritis nodosa revisited. Curr. Rheumatol. Rep. 7: 288-296 (2005).

• Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56: 1966-1973 (2007). *

• Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 69: 1846-1851 (2006). *

• Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14 Suppl. 1: s33-s38 (2005).

• Cornell LD, Chicano SL, Deshpande V, Collins AB, Selig MK, Lauwers GY, Barisoni L, Colvin RB. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease. Am. J. Surg. Pathol. 31: 1586-1597 (2007).

• Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14: 1-6 (2000). *

• Cortes-Hernandez J, Fossati-Jimack L, Petry F, Loos M, Izui S, Walport MJ, Cook HT, Botto M. Restoration of C1q levels by bone marrow transplantation attenuates autoimmune disease associated with C1q deficiency in mice. Eur. J. Immunol. 34: 3713-3722 (2004). *

• Covic A, Mutica C, Ignat A, Boaru I, Veisa G, Gusbeth-Tatomir P, Enea M, Covic M. Retrospective study of 97 ANCA-positive patients: epidemiological and clinical spectrum. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 305-310 (2004).

• Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181: 8761-8766 (2008).

• Cristea A, Badea T, Bodizs G, Olinic N. Antineutrophil cytoplasmic autoantibodies (ANCA) - markers in diagnosis and monitoring systemic vasculitides. Rom. J. Intern. Med. 33: 37-46 (1995).

• Croker BP, Gilkeson G, Morel L. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun. 4: 575-585 (2003). *

• Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, Foster MH, Coffman TM. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J. Clin. Invest. pii: 34862 (2009). *

• Cua IH, Kwan V, Henriquez M, Kench J, George J. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut 55: 1521-1522 (2006). *

• Cui GM, Liu G, Liu W, Kan B, Mao YQ, Wei YQ. Experimental study of pristane-induced murine lupus model. Sichuan Da Xue Xue Bao Yi Xue Ban 37: 309-312 (2006).

• Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig. Dis. 15: 125-144 (1997).

• D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 369: 587-596 (2007). *

• Damoiseaux JG, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Cohen Tervaert JW. Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J. Clin. Immunol. 25: 202-208 (2005). *

• Daskas N, Farmer K, Coward R, Erlewyn-Lajeunesse M. Meningococcal disease associated with an acute post-streptococcal complement deficiency. Pediatr. Nephrol. 22: 747-749 (2007).

• Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr. Opin. Rheumatol. 18: 468-475 (2006).

• Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus 14: 197-203 (2005).

• Davies PJ. Mozart's illnesses and death. J. R. Soc. Med. 76: 776-785 (1983). *

• De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol. Dial. Transplant. 12: 1839-1841 (1997). *

• de Groot K, Schnabel A. Pulmonary-renal syndrome. Internist (Berl.) 46: 769-782 (2005).

• De Jager PL, Graham R, Farwell L, Sawcer S, Richardson A, Behrens TW, Compston A, Hafler DA, Kere J, Vyse TJ, Rioux JD. The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus. Genes Immun. 7: 327-334 (2006). *

• De Jager PL, Richardson A, Vyse TJ, Rioux JD. Genetic variation in Toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum. 54: 1279-1282 (2006). *

• de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm. Bowel Dis. 11: 972-976 (2005). *

• De Sanctis LB, Mandreoli M, Poggi C, Pileri S, Casanova S, Santoro A. Acute renal failure in a young woman with Fisher-Evans' syndrome. J. Nephrol. 17: 739-743 (2004).

• De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig. Liver Dis. 39 Suppl. 1: S122-S128 (2007).

• De-Leon-Bojorge B, Zaltzman-Girsevich S, Ortega-Salgado A, Prieto-Patron A, Cordoba-Cordoba R, Yamazaki-Nakashimada M. Thrombotic microangiopathy involving the gallbladder as an unusual manifestation of systemic lupus erythematosus and antiphospholipid syndrome: case report and review of the literature. World J. Gastroenterol. 12: 7206-7209 (2006). *

• Deak G, Ruzicska E, Somogyi A. Association of IgA nephropathy, hypothyroidism and hypercholesterolemia. J. Nephrol. 18: 773-776 (2005).

• Dean EG, Wilson GR, Li M, Edgtton KL, O'sullivan KM, Hudson BG, Holdsworth SR, Kitching AR. Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int. 67: 566-575 (2005). *

• Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J. Immunol. 181: 4019-4026 (2008).

• Denkinger CM, Metz C, Fingerle-Rowson G, Denkinger MD, Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz.) 52: 389-400 (2004).

• Deshpande V, Mino-Kenudson M, Brugge W, Lauwers GY. Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology. Arch. Pathol. Lab. Med. 129: 1148-1154 (2005). *

• Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol. 18: 321-326 (2004).

• Diaz Rodriguez C, Gonzalez Rivero C, Trinidad San Jose JC, Del Rio Romero D, Moreno Fernandez A, Granja Romero E. Osteal complications as first manifestation in a patient with primary Sjogren's syndrome and with associated distal tubular acidosis (type 1) and chronic renal insufficiency. Therap. Apher. Dial. 8: 160-163 (2004).

• Diaz Rodriguez C, Granja E, Vazquez Martul E, Sacristan F, Moreno Fernandez A, Gonzalez Rivero C, del Rio Romero D, Trinidad JC. Association between membranous glomerulonephritis and Crohn's disease. Nefrologia 24: 368-371 (2004).

• Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, Sluiter WJ, Limburg PC, Derksen RH, van de Winkel JG, Kallenberg CG. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum. 43: 2793-2800 (2000). *

• do Nascimento AP, Dos Santos Trindade Viana V, de Abreu Testagrossa L, Leon EP, Borba EF, Barros RT, Bonfa E. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum. 54: 1568-1572 (2006). *

• Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC. Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 16: 101-109 (2007).

• Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52: 651-658 (2005). *

• Dooley MA, Falk RJ. Human clinical trials in lupus nephritis. Semin. Nephrol. 27: 115-127 (2007).

• Douglas G, Reilly C, Dooley MA, Page G, Cooper G, Gilkeson G. Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. J. Rheumatol. 31: 1756-1762 (2004).

• Du H, Chen M, Zhang Y, Zhao MH. Non-DNA-binding antibodies in patients with lupus nephritis could recognize membrane proteins of glomerular sesangial cells. J. Clin. Immunol. 26: 138-144 (2006). *

• Du Y, Fu Y, Mohan C. Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch. Immunol. Ther. Exp. (Warsz.) 56: 31-40 (2008).

• Duan B, Croker BP, Morel L. Lupus resistance is associated with marginal zone abnormalities in an NZM murine model. Lab. Invest. 87: 14-28 (2007). *

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 22: 245-260 (1995).

• Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC. Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol. 112: 203-208 (2004).

• Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression. Case report. Pediatr. Nephrol. 20: 811-813 (2005). *

• Edwards CK 3rd, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J. Immunol. 157: 1758-1772 (1996).

• Egido J, Ruiz-Ortega M. Anti-inflammatory actions of quinapril. Cardiovasc. Drugs Ther. 21: 211-220 (2007).

• Eisenhut M. Changes in ion transport in inflammatory disease. J. Inflamm. (Lond.) 3: 5 (2006). *

• Eisenmann A, Murr C, Fuchs D, Ledochowski M. Gliadin IgG antibodies and circulating immune complexes. Scand. J. Gastroenterol. 44: 168-171 (2009). *

• El-Sehemy MS, Al-Saaran AM, Baddour NM, Adam AG, Moez PE. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. Egypt. J. Immunol. 13: 39-52 (2006).

• Elizur SE, Chian RC, Pineau CA, Son WY, Holzer HE, Huang JY, Gidoni Y, Levin D, Demirtas E, Tan SL. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford) 47: 1506-1509 (2008). *

• Ellerbroek PM, Oudkerk Pool M, Ridwan BU, Dolman KM, von Blomberg BM, von dem Borne AE, Meuwissen SG, Goldschmeding R. Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J. Clin. Pathol. 47: 257-262 (1994). *

• Elseviers MM, D'Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, Capasso G, Van Outryve M, Mishevska-Mukaetova P, Djuranovic S, Pelckmans P, De Broe ME; 5-ASA Study Group. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin. Nephrol. 61: 83-89 (2004).

• Enriquez E, Borras-Blasco J, Sirvent AE, Masia M, Amoros F. Early onset neutropenia after rituximab in lupus nephritis. Clin. Exp. Rheumatol. 25: 345 (2007).

• Ernandez T, Mayadas T. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int. May 13 [Epub ahead of print] (2009).

• Esashi E, Ito H, Minehata KI, Saito S, Morikawa Y, Miyajima A. Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. Eur. J. Immunol. Apr 21 [Epub ahead of print] (2009),. *

• Escribese MM, Conde E, Martin A, Saenz-Morales D, Sancho D, Perez de Lema G, Lucio-Cazana J, Sanchez-Madrid F, Garcia-Bermejo ML, Mampaso FM. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin. BMC Nephrol. 8: 3 (2007). *

• Escribese MM, Conde E, Saenz-Morales D, Hordijk PL, Garcia-Bermejo ML. Mononuclear cells extravasation in an inflammatory response is abrogated by all trans retinoic acid (at-RA) through inhibiting the acquisition of an appropriate migratory phenotype. J. Pharmacol. Exp. Ther. 324: 454-462 (2008). *

• Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J. Clin. Gastroenterol. 42: 862-863 (2008).

• Fairhurst AM, Hwang SH, Wang A, Tian XH, Boudreaux C, Zhou XJ, Casco J, Li QZ, Connolly JE, Wakeland EK. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur. J. Immunol. 38: 1971-1978 (2008). *

• Falasca L, Iadevaia V, Ciccosanti F, Melino G, Serafino A, Piacentini M. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J. Immunol. 174: 7330-7340 (2005). *

• Fathi NA, Hussein MR, Hassan HI, Mosad E, Galal H, Afifi NA. Glomerular expression and elevated serum Bcl-2 and Fas proteins in lupus nephritis: preliminary findings. Clin. Exp. Immunol. 146: 339-343 (2006). *

• Feist E, Hermann KG, Dankof A. Vasculopathy in Sjogren's syndrome. Z. Rheumatol. 68: 305-311 (2009).

• Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J. Am. Soc. Nephrol. 17: 1243-1252 (2006). *

• Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. ApoE-/-Fas-/-C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis and osteopenia. J. Lipid Res. 48: 794-805 (2007). *

• Feng X, Wu H, Grossman JM, Hanvivadhanakul P, Fitzgerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2951-2962 (2006). *

• Fernandes PF, Junior GB, Barros FA, Sousa DC, Franco LM, Patrocinio RM. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review. Invest. Clin. 47: 405-411 (2006).

• Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vila LM, Reveille JD; LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 57: 576-584 (2007). *

• Ferrantelli A, Bono L, Tortorici C, Termini R, Giammarresi C, Rotolo U. Treatment of lupus nephritis. G. Ital. Nefrol. 22: S27-33 (2005).

• Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: ANCA-associated vasculitis (first part). J. Nephrol. 18: 113-116 (2005).

• Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: ANCA-associated vasculitis (second part). J. Nephrol. 18: 217-220 (2005).

• Ferrera F, Hahn BH, Rizzi M, Anderson M, Fitzgerald J, Millo E, Indiveri F, Shi FD, Filaci G, La Cava A. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum. 56: 1945-1953 (2007). *

• Ferri C. Mixed cryoglobulinemia. Orphanet J. Rare Dis. 3: 25 (2008). *

• Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patino R. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J. Rheumatol. 33: 1980-1986 (2006).

• Finetti F, Pellegrini M, Ulivieri C, Savino MT, Paccagnini E, Ginanneschi C, Lanfrancone L, Pelicci PG, Baldari CT. The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity. Blood 111: 5017-5027 (2008). *

• Finke D, Randers K, Hoerster R, Hennig H, Zawatzky R, Marion T, Brockmann C, Klempt-Giessing K, Jacobsen K, Kirchner H, Goerg S. Elevated levels of endogenous apoptotic DNA and IFN-alpha in complement C4-deficient mice: implications for induction of systemic lupus erythematosus. Eur. J. Immunol. 37: 1702-1709 (2007). *

• Fischer-Betz R, Hiepe F. Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology: comment on the use of mycophenolic acid for systemic lupus erythematosus. Z. Rheumatol. 66: 78-82 (2007).

• Flanders KC, Burmester JK. Medical applications of transforming growth factor-beta. Clin. Med. Res. 1: 13-20 (2003). *

• Fletcher CA, Sutherland AP, Groom JR, Batten ML, Ng LG, Gommerman J, Mackay F. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36: 2504-2514 (2006). *

• Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis - a hypothesis. Mol. Immunol. 44: 133-138 (2007). *

• Flower C, Hennis A, Hambleton IR, Nicholson G. Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. Lupus 15: 689-694 (2006).

• Fofi C, Nicoletti MC, Onetti-Muda A, Giulio S. Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis. G. Ital. Nefrol. 20: 641-644 (2003).

• Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J. Clin. Rheumatol. 7: 340-345 (2001).

• Foocharoen C, Nanagara R, Salang L, Suwannaroj S, Mahakkanukrauh A. Pregnancy and disease outcome in patients with systemic lupus erythematosus (SLE): a study at Srinagarind Hospital. J. Med. Assoc. Thai. 92: 167-174 (2009).

• Forster N, Gallinat S, Jablonska J, Weiss S, Elsasser HP, Lutz W. p300 Protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice. J. Immunol. 178: 6941-6948 (2007). *

• Foster MH. T cells and B cells in lupus nephritis. Semin. Nephrol. 27: 47-58 (2007).

• Fracchia M, Manganaro M, Poccardi G, Pera A, Galatola G. Minimal change nephropathy presenting in a patient with primary sclerosing cholangitis. Ital. J. Gastroenterol. Hepatol. 29: 267-269 (1997).

• Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 92: 200-202 (2002).

• Fronek Z, Timmerman LA, Alper CA, Hahn BH, Kalunian K, Peterlin BM, McDevitt HO. Major histocompatibility complex associations with systemic lupus erythematosus. Am. J. Med. 85: 42-44 (1988).

• Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res. Ther. 10: R112 (2008). *

• Fujii A, Yamaguchi Y, Horita S, Yumura W, Fuchinoue S, Teraoka S. Early recurrence of lupus nephritis after renal transplantation - a case report. Clin. Transplant. 20 Suppl. 15: 42-45 (2006).

• Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K. Bullous systemic lupus erythematosus as an initial manifestation of SLE. J. Dermatol. 32: 1021-1027 (2005).

• Fujimura T, Hirose S, Jiang Y, Kodera S, Ohmuro H, Zhang D, Hamano Y, Ishida H, Furukawa S, Shirai T. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int. Immunol. 10: 1467-1472 (1998). *

• Fujio K, Okamoto A, Tahara H, Abe M, Jiang Y, Kitamura T, Hirose S, Yamamoto K. Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J. Immunol. 173: 2118-2125 (2004). *

• Fujio K, Okamura T, Okamoto A, Yamamoto K. T cell receptor gene therapy for autoimmune diseases. Ann. N. Y. Acad. Sci. 1110: 222-232 (2007). *

• Galindo M, Cabello A, Joven B, Alonso A, Carreira P, Porta J, Ricoy JR, Mateo I, Pablos JL. Mycophenolate mofetil induced myopathy in a patient with lupus nephritis. J. Rheumatol. 32: 188-190 (2005).

• Gallego F, Gelpi C. The IL-12 role in donor cell engraftment in a murine model of semiallogenic GVH disease with signs of autoimmune disease. Autoimmunity 37: 155-170 (2004).

• Gallelli B, De Angelis V, Ventura D, Meroni PL, Moroni G. SLE: extra-renal clinical manifestations and lupus nephritis. G. Ital. Nefrol. 22: S3-S10 (2005).

• Garcia-Diaz M, Nevado L, Berenguer A, Bureo JC, Bureo P, Saenz de Santamaria J. Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterol. Hepatol. 18: 18-21 (1995).

• Geffriaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin. Nephrol. 39: 125-136 (1993).

• Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin. Exp. Rheumatol. 22: 749-755 (2004).

• Gelmetti AP, Freitas AC, Woronik V, Barros RT, Bonfa E, Monteiro RC. Polymorphism of the FcgRIIa IgG receptor in patients with lupus nephritis and glomerulopathy. J. Rheumatol. 33: 523-530 (2006).

• Genton C, Wang Y, Izui S, Malissen B, Delsol G, Fournie GJ, Malissen M, Acha-Orbea H. The Th2 lymphoproliferation developing in LatY136F mutant mice triggers polyclonal B cell activation and systemic autoimmunity. J. Immunol. 177: 2285-2293 (2006). *

• Gerber NL, Steinberg AD. Clinical use of immunosuppressive drugs: part II. Drugs 11: 90-112 (1976).

• Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 15: 148-155 (2006).

• Gibson A, Stamp LK, Chapman PT, O'Donnell JL. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 45: 624-628 (2006). *

• Gigante A, Amoroso D, Ferri F, Gianni C, Coppolino G, Papa A, Amoroso A. Systemic lupus erythematosus and renal involvement: which role of citokines expression? Eur. Rev. Med. Pharmacol. Sci. 10: 223-228 (2006).

• Gionanlis L, Alexopoulos E, Papagianni A, Leontsini M, Memmos D. Fibrotic mechanisms in idiopathic rapidly progressive glomerulonephritis: the role of TGF-beta1 and C5b-9. Ren. Fail. 30: 239-246 (2008).

• Giorgini A, Noble A. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts. J. Leukoc. Biol. 82: 1053-1061 (2007). *

• Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 13: 629-638 (2007). *

• Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol. Hepatol. 31: 477-484 (2008).

• Giscombe R, Wang XB, Kakoulidou M, Lefvert AK. Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Intern. Med. 260: 224-230 (2006). *

• Go KW, Teo SM. Treatment and renal outcome of lupus nephritis: single center experience. Med. J. Malaysia 61: 447-450 (2006).

• Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun. Rev. 7: 606-611 (2008).

• Gong R, Liu Z, Li L. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Arthritis Rheum. 56: 1608-1617 (2007). *

• Good RA. Cellular immunology in a historical perspective. Immunol. Rev. 185: 136-158 (2002). *

• Good RA. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases. World J. Surg. 24: 797-810 (2000). *

• Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alen J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18: 257-263 (2009).

• Goto A, Mukai M, Notoya A, Kohno M. Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report. Mod. Rheumatol. 15: 118-122 (2005).

• Goto T, Komatsu M, Fujii T, Ohshima S, Nakane K, Yoneyama K, Shibuya T, Meng XW, Masamune O, Imai H. Primary biliary cirrhosis associated with membranous glomerulonephritis. Intern. Med. 38: 22-26 (1999). *

• Gould KA, Strecker TE, Hansen KK, Bynote KK, Peterson KA, Shull JD. Genetic mapping of loci controlling diethylstilbestrol-induced thymic atrophy in the Brown Norway rat. Mamm. Genome 17: 451-464 (2006). *

• Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 26: 165-171 (2006).

• Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. 5 Suppl. 4: S22-S27 (2003). *

• Grech V, Vella C. Henoch-Schoenlein purpura with nephritis in two siblings following infectious mononucleosis. Ann. Trop. Paediatr. 22: 297-298 (2002).

• Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27: 308-320 (2007). *

• Greidinger EL, Zang Y, Jaimes K, Hogenmiller S, Nassiri M, Bejarano P, Barber GN, Hoffman RW. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum. 54: 661-669 (2006). *

• Greidinger EL, Zang Y, Martinez L, Jaimes K, Nassiri M, Bejarano P, Barber GN, Hoffman RW. Differential tissue targeting of autoimmunity manifestations by autoantigen-associated Y RNAs. Arthritis Rheum. 56: 1589-1597 (2007). *

• Gribar SC, Richardson WM, Sodhi CP, Hackam DJ. No longer an innocent bystander: epithelial Toll-like receptor signaling in the development of mucosal inflammation. Mol. Med. 14: 645-659 (2008). *

• Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 56: 924-937 (2007). *

• Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, Daha MR, Berden JH. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann. Rheum. Dis. 66: 693-696 (2007). *

• Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70: 732-742 (2006). *

• Gros C, Delesalle F, Gautier S, Delaporte E. Leflunomide-induced skin necrosis. Ann. Dermatol. Venereol. 135: 205-208 (2008).

• Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60: 14-30 (2001). *

• Gubbels MR, Jorgensen TN, Metzger TE, Menze K, Steele H, Flannery SA, Rozzo SJ, Kotzin BL. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J. Immunol. 175: 6190-6196 (2005). *

• Guerini S, Cavazzana I, Venturelli C, Rozzi M, Turina S, Sottini L, Tardanico R, Franceschini F, Scolari F. Kidney in systemic sclerosis. G. Ital. Nefrol. 24: 295-310 (2007).

• Guilherme L, Postol E, Barros SF, Higa F, Alencar R, Lastre M, Zayas C, R Puschel C, R Silva W, C Sa-Rocha L, M Sa-Rocha V, Perez O, Kalil J. A vaccine against S. pyogenes: design and experimental immune response. Methods Apr 29 [Epub ahead of print] (2009).

• Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br. J. Rheumatol. 36: 1089-1094 (1997).

• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56: 1263-1272 (2007). *

• Gurkan S, Dikman S, Saland MJ. A case of autoimmune thyroiditis and membranoproliferative glomerulonephritis. Pediatr. Nephrol. 24: 193-197 (2009).

• Gutierrez-Adrianzen OA, Koutouzov S, Mota RM, das Chagas Medeiros MM, Bach JF, Campos HD. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J. Rheumatol. 33: 1538-1544 (2006).

• Gutkowski K, Gutkowska D. Systemic lupus erythematosus (SLE). Ginekol. Pol. 77: 893-900 (2006).

• Haake H, Koneke J, Amann K, Vom Dahl J, Janssen U. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med. Klin. (Munich) 102: 852-857 (2007).

• Hadj-Kacem H, Rebuffat S, Mnif-Feki M, Belguith-Maalej S, Ayadi H, Peraldi-Roux S. Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions. Int. J. Immunogenet. 36: 85-96 (2009). *

• Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 53: 743-753 (1998). *

• Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann. N. Y. Acad. Sci. 1051: 433-441 (2005). *

• Halim MA, Said T, Nair P, Schmidt I, Hassan A, Johny KV, Al-Muzairai I, Samhan M, Nampoory MR, Al-Mousawi M. De novo Crohn's disease in a renal transplant recipient. Transplant. Proc. 39: 1278-1279 (2007). *

• Hamblin TJ. Non-hemic autoimmunity in CLL. Leuk. Res. 33: 366-367 (2009).

• Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A. Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin. Rheumatol. 25: 542-543 (2006). *

• Hamling J, Raedler A, Helmchen U, Schreiber S. 5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion 58: 304-307 (1997).

• Han B, Moore PA, Wu J, Luo H. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum. 56: 3748-3758 (2007). *

• Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y, Nagata S. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304: 1147-1150 (2004). *

• Hao CM, Breyer MD. Roles of lipid mediators in kidney injury. Semin. Nephrol. 27: 338-351 (2007).

• Harboe E, Goransson L, Wildhagen K, Omdal R. Mycophenolate mofetil: a new therapeutic agent for chronic autoimmune diseases. Tidsskr. Nor. Laegeforen. 125: 1650-1652 (2005).

• Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3: 707-715 (2007). *

• Hashii N, Kawasaki N, Itoh S, Nakajima Y, Kawanishi T, Yamaguchi T. Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of N-glycans using an isotope-tagging method. Immunology 126: 336-345 (2009). *

• Hatakeyama T, Komatsuda A, Matsuda A, Togashi M, Maki N, Masai R, Sawada K, Wakui H. Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin. Nephrol. 70: 240-244 (2008).

• Hatano T, Fukuda M, Shiotsuki H, Miwa H, Urabe T, Mizuno Y. Chronic inflammatory demyelinating polyneuropathy followed by systemic lupus erythematosus and Sjogren syndrome: a case report. Rinsho Shinkeigaku 46: 203-209 (2006).

• Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus 16: 227-231 (2007).

• Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC; European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 61: 80-89 (2002). *

• Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, Druez P, Omar M, Kockx M, Hubens H, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J. Hepatol. 22: 71-77 (1995). *

• Havarinasab S, Hultman P. Alteration of the spontaneous systemic autoimmune disease in (NZB x NZW)F1 mice by treatment with thimerosal (ethyl mercury). Toxicol. Appl. Pharmacol. 214: 43-54 (2006). *

• Hayashi T, Hasegawa K, Sasaki Y, Mori T, Adachi C, Maeda K. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB x NZW F1 mice. Nephrol. Dial. Transplant. 22: 3131-3138 (2007).

• Haywood ME, Rose SJ, Horswell S, Lees MJ, Fu G, Walport MJ, Morley BJ. Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal novel lupus candidate genes. Genes Immun. 7: 250-263 (2006). *

• He X, Schoeb TR, Panoskaltsis-Mortari A, Zinn KR, Kesterson RA, Zhang J, Samuel S, Hicks MJ, Hickey MJ, Bullard DC. Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J. Immunol. 177: 8748-8756 (2006). *

• Heidari Y, Bygrave AE, Rigby RJ, Rose KL, Walport MJ, Cook HT, Vyse TJ, Botto M. Identification of chromosome intervals from 129 and C57BL/6 mouse strains linked to the development of systemic lupus erythematosus. Genes Immun. 7: 592-599 (2006). *

• Heidari Y, Fossati-Jimack L, Carlucci F, Walport MJ, Cook HT, Botto M. A lupus-susceptibility C57BL/6 locus on chromosome 3 (Sle18) contributes to autoantibody production in 129 mice. Genes Immun. 10: 47-55 (2009). *

• Heinonen KM, Nestel FP, Newell EW, Charette G, Seemayer TA, Tremblay ML, Lapp WS. T cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood 103: 3457-3464 (2004). *

• Herrera-Esparza R, Aguilar JL, Saucedo A, Gonzalez I, Lopez-Robles E, Avalos-Diaz E. Scleroderma with type III glomerulonephritis and MPO-ANCA antibodies in the serum. J. Eur. Acad. Dermatol. Venereol. 19: 617-620 (2005).

• Heyman SN, Spectre G, Aamar S, Rubinger D, Pappo O, Ackerman Z. Autoimmune cholangiopathy associated with systemic lupus erythematosus. Liver 22: 102-106 (2002).

• Hicks J, Bullard DC. Review of autoimmune (lupus-like) glomerulonephritis in murine models. Ultrastruct. Pathol. 30: 345-359 (2006). *

• Hirabayashi Y. The role of cell stress in systemic autoimmune disease. Nihon Rinsho Meneki Gakkai Kaishi 29: 65-72 (2006). *

• Hirai Y, Iyoda M, Shibata T, Ashikaga E, Hosaka N, Suzuki H, Nagai H, Mukai M, Honda H, Kuroki A, Kitazawa K, Akizawa T. Lupus nephritis associated with positive MPO-ANCA in a patient with underlying autoimmune hemolytic anemia. Clin. Exp. Nephrol. 12: 393-397 (2008).

• Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M. Long-term prognosis of autoimmune pancreatitis without and with corticosteroid treatment. Gut 56: 1719-1724 (2007). *

• Hirashima M, Fukazawa T, Abe K, Morita Y, Kusaoi M, Hashimoto H. Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus 13: 24-31 (2004).

• Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku C, Fukazawa T, Bejrachandra S, Siriboonrit U, Chandanayingyong D, Suthipinittharm P, Tsao BP, Hashimoto H, Honda Z, Tokunaga K. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum. Mol. Genet. 13: 2907-2917 (2004). *

• Hoffmeister A, Wittenburg H, Teich N, Bachmann A, Borte G, Mossner J, Achenbach H. A 32-year-old patient with diarrhoe and acute kidney failure. Internist (Berl.) 47: 1063-1067 (2006).

• Hoi AY, Hickey MJ, Hall P, Yamana J, O'sullivan KM, Santos LL, James WG, Kitching AR, Morand EF. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J. Immunol. 177: 5687-5696 (2006). *

• Hong Y, Huang C, Wang S, Lin B. The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice. Lupus 18: 206-215 (2009).

• Hoshi D, Okamoto H, Kaneko H, Ichikawa N, Terai C, Yamanaka H, Kamatani N. Association of a polymorphism in the monocyte chemoattractant protein-1/CCL2 gene and lupus nephritis in systemic lupus erythematosus patients. Clin. Exp. Rheumatol. 26: 972-973 (2008).

• Hoshi N, Watanabe H, Kobayashi H, Sekine H, Hoshi N, Sugino T, Suzuki T, Sato Y, Ohira H. Inhibitory oligodeoxynucleotide improves glomerulonephritis and prolongs survival in MRL-lpr/lpr mice. Fukushima J. Med. Sci. 53: 70-84 (2007).

• Hoshino A, Nagao T, Nagi-Miura N, Ohno N, Yasuhara M, Yamamoto K, Nakayama T, Suzuki K. MPO-ANCA induces IL-17 production by activated neutrophils in vitro via its Fc region- and complement-dependent manner. J. Autoimmun. 31: 79-89 (2008).

• Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus 16: 212-216 (2007).

• Hovinga IC, Koopmans M, Baelde HJ, Wal AM, Sijpkens YW, Heer ED, Bruijn JA, Bajema IM. Chimerism occurs twice as often in lupus nephritis as in normal kidneys. Arthritis Rheum. 54: 2944-2950 (2006). *

• Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell W, Beckett P, Ali MA, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 60: 1012-1018 (2005). *

• Hsu HC, Zhou T, Kim H, Barnes S, Yang P, Wu Q, Zhou J, Freeman BA, Luo M, Mountz JD. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis Rheum. 54: 343-355 (2005). *

• Hu DC, Cathro HP, Okusa MD. Polymorphoneutrophilic infiltration in acute interstitial nephritis of Sjogren syndrome. Am. J. Med. Sci. 327: 278-280 (2004).

• Huang CM, Wu MC, Wu JY, Tsai FJ. Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 11: 31-34 (2002).

• Huang H, Peng Y, Liu F, Lei H. Is IgA nephropathy induced by abnormalities of CD4(+)CD25(+)Treg cells in the tonsils? Med. Hypotheses 69: 410-413 (2007).

• Huang WC, Lien SH, Chang DM, Lu JJ, Cheng SN. Monozygotic twins concordant for idiopathic thrombocytopenic purpura and discordant for systemic lupus erythematosus and lupus nephritis. Eur. J. Pediatr. 166: 497-500 (2007). *

• Hubert D, Beaufils M, Meyrier A. Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases. Presse. Med. 13: 1083-1085 (1984).

• Hunt BJ, Tueger S, Pattison J, Cavenagh J, D'Cruz DP. Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus 16: 358-362 (2007).

• Huugen D, Cohen Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin. J. Am. Soc. Nephrol. 1: 1100-1107 (2006). *

• Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am. J. Pathol. 167: 47-58 (2005). *

• Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun. Rev. 6: 190-195 (2007). *

• Ichii O, Konno A, Sasaki N, Endoh D, Hashimoto Y, Kon Y. Autoimmune glomerulonephritis induced in congenic mouse strain carrying telomeric region of chromosome 1 derived from MRL/MpJ. Histol. Histopathol. 23: 411-422 (2008).

• Ichii O, Konno A, Sasaki N, Endoh D, Hashimoto Y, Kon Y. Altered balance of inhibitory and active Fc gamma receptors in murine autoimmune glomerulonephritis. Kidney Int. 74: 339-347 (2008).

• Ichii O, Konno A, Sasaki N, Endoh D, Hashimoto Y, Kon Y. Onset of autoimmune glomerulonephritis derived from the telomeric region of MRL-chromosome 1 is associated with the male sex hormone in mice. Lupus 18: 491-500 (2009).

• Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell immunity and graft-versus-host disease (GVHD). Autoimmun. Rev. 5: 1-9 (2006).

• Igawa T, Nakashima H, Sadanaga A, Masutani K, Miyake K, Shimizu S, Takeda A, Hamano S, Yoshida H. Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod. Rheumatol. 19: 33-41 (2009). *

• Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today (Barc.) 38: 103-111 (2002).

• Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol. 99: 116-132 (1998).

• Inokuchi Y, Morohashi T, Kawana I, Nagashima Y, Kihara M, Umemura S. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 54: 349-356 (2005). *

• Isenberg D, Lesavre P. Lupus nephritis: assessing the evidence, considering the future. Lupus 16: 210-211 (2007).

• Ishida D, Su L, Tamura A, Katayama Y, Kawai Y, Wang SF, Taniwaki M, Hamazaki Y, Hattori M, Minato N. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity 24: 417-427 (2006). *

• Ishikawa S, Matsushima K. Aberrant B1 cell trafficking in a murine model for lupus. Front. Biosci. 12: 1790-1803 (2007).

• Isome M, Suzuki J, Takahashi A, Murai H, Nozawa R, Suzuki S, Kawasaki Y, Suzuki H. Epstein-Barr virus-associated hemophagocytic syndrome in a patient with lupus nephritis. Pediatr. Nephrol. 20: 226-228 (2005).

• Ito S, Nakamura T, Kurosawa R, Miyamae T, Imagawa T, Mori M, Aihara Y, Yokota S. Glomerulonephritis in children with mixed connective tissue disease. Clin. Nephrol. 66: 160-165 (2006).

• Ivanova A, Ivanov S, Pascal V, Lumsden J, Ward J, Morris N, Tessarolo L, Anderson S, Lerman M. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J. Pathol. 211: 591-601 (2007). *

• Iwai H, Lee S, Inaba M, Baba S, Yamashita T, Ikehara S. Bone marrow transplantation as a strategy for the treatment of autoimmune hearing loss in MRL/Mp-lpr/lpr mice. J. Neuroimmunol. 168: 76-82 (2005).

• Iwai M, Harada Y, Ishii M, Tanaka S, Muramatsu A, Mori T, Nakashima T, Okanoue T, Hirohata S. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin. Rheumatol. 22: 234-236 (2003). *

• Iyoda M, Ito J, Nagai H, Sato K, Kuroki A, Shibata T, Kitazawa K, Sugisaki T. Microscopic polyangiitis after silicone breast implantation. Clin. Exp. Nephrol. 9: 252-254 (2005).

• Izzedine H, Brocheriou I, Valantin MA, Camous L, Bourry E, Baumelou A, Deray G, Katlama C. A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome. Nat. Clin. Pract. Nephrol. 4: 110-114 (2008). *

• Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. 177: 2671-2680 (2006). *

• Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand mixed 2328 bice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J. Immunol. 182: 2532-2541 (2009).

• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84: 223-243 (1997).

• Jaekell HP, Trabandt A, Grobe N, Werle E. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus 15: 335-345 (2006).

• Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E, Csernok E, Gross WL, Epplen JT. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum. Genet. 114: 468-477 (2004). *

• Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener granulomatosis. Autoimmun. Rev. 4: 42-47 (2005). *

• Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, Ronco P, Rondeau E, Fain O. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine (Baltimore) 86: 170-180 (2007).

• Javouhey E, Ranchin B, Lachaux A, Boillot O, Martin X, Floret D, Cochat P. Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis. Pediatr. Transplant. 13: 235-239 (2009).

• Jayne D. Current management of lupus nephritis: popular misconceptions. Lupus 16: 217-220 (2007).

• Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13: 168-176 (2004).

• Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R, Diaz M. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol. 178: 7422-7431 (2007). *

• Jiang C, Zhao ML, Diaz M. Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis. Immunology 126: 102-113 (2009). *

• Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis … Arthritis Rheum. 58: 1226-1236 (2008). *

• Jinguji Y, Nukui I, Wakasugi M, Yamashita H. Two cases of systemic lupus erythematosus complicated by hydronephrosis and unique small structures observed in the glomerular basement membrane. Clin. Exp. Nephrol. 12: 467-474 (2008).

• Jog NR, Dinnall JA, Gallucci S, Madaio MP, Caricchio R. Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J. Immunol. 182: 7297-7306 (2009).

• Jones DB, Coulson AF, Duff GW. Sequence homologies between hsp60 and autoantigens. Immunol. Today 14: 115-118 (1993).

• Jones DS. Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases. Curr. Med. Chem. 12: 1887-1904 (2005).

• Jonsen A, Gunnarsson I, Gullstrand B, Svenungsson E, Bengtsson AA, Nived O, Lundberg IE, Truedsson L, Sturfelt G. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 46: 1417-1421 (2007). *

• Jorgensen TN, Thurman J, Izui S, Falta MT, Metzger TE, Flannery SA, Kappler J, Marrack P, Kotzin BL. Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice. Genes Immun. 7: 555-567 (2006). *

• Ju ZL, Shi GY, Zuo JX, Zhang JW, Sun J. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology 120: 281-289 (2007). *

• Kadokawa Y, Omagari K, Matsuo I, Otsu Y, Yamamoto U, Nishino T, Ohba K, Miyazaki M, Harada T, Taguchi T, Kohno S. Primary sclerosing cholangitis associated with lupus nephritis: a rare association. Dig. Dis. Sci. 48: 911-914 (2003). *

• Kahn P, Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Factor SM, Davidson A. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 58: 2824-2834 (2008). *

• Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P, Rekvig OP. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 71: 664-672 (2007). *

• Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am. J. Pathol. 168: 1779-1792 (2006). *

• Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum. 54: 914-926 (2006). *

• Kalden JR. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists. Curr. Opin. Rheumatol. 6: 281-286 (1994).

• Kalergis AM, Iruretagoyena MI, Barrientos MJ, Gonzalez PA, Herrada AA, Leiva ED, Gutierrez MA, Riedel CA, Bueno SM, Jacobelli SH. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology Nov 7 [Epub ahead of print] (2008). *

• Kallen KJ, Galle PR, Rose-John S. New developments in IL-6 dependent biology and therapy: where do we stand and what are the options? Expert Opin. Investig. Drugs 8: 1327-1349 (1999).

• Kallenberg CG. Laboratory findings in the vasculitides. Baillieres Clin. Rheumatol. 11: 395-421 (1997).

• Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr. Opin. Rheumatol. 19: 17-24 (2007).

• Kallenberg CG, Mulder AH, Tervaert JW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am. J. Med. 93: 675-682 (1992).

• Kamei K, Nakagawa A, Otsuka Y, Nakayama M, Kobayashi S, Matsuoka K, Iijima K. Chronic glomerulonephritis associated with IgG subclass deficiency. Pediatr. Nephrol. 22: 1229-1234 (2007).

• Kamijo Y, Hora K, Nakajima T, Kono K, Takahashi K, Ito Y, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J. Am. Soc. Nephrol. 18: 176-188 (2007). *

• Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J. Gastroenterol. 14: 3948-3955 (2008). *

• Kane S. Urogenital complications of Crohn's disease. Am. J. Gastroenterol. 101: S640-S643 (2006).

• Kang HK, Datta SK. Regulatory T cells in lupus. Int. Rev. Immunol. 25: 5-25 (2006).

• Kang HK, Ecklund D, Liu M, Datta SK. Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res. Ther. 11: R59 (2009). *

• Kang TY, El-Sohemy A, Comelis MC, Eny KM, Bae SC. Glutathione S-transferase genotype and risk of systemic lupus erythematosus in Koreans. Lupus 14: 381-384 (2005).

• Karahan GE, Seyhun Y, Oguz FS, Kekik C, Onal AE, Yazici H, Turkmen A, Aydin AE, Sever MS, Eldegez U, Carin MN. Impact of HLA on the underlying primary diseases in Turkish patients with end-stage renal disease. Ren. Fail. 31: 44-49 (2009).

• Karassa FB, Trikalinos TA, Ioannidis JP. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed. Pharmacother. 58: 286-291 (2004).

• Karassa FB, Trikalinos TA, Ioannidis JP; FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 46: 1563-1571 (2002). *

• Karathanasis E, Geigerman CM, Parkos CA, Chan L, Bellamkonda RV, Jaye DL. Selective targeting of nanocarriers to neutrophils and monocytes. Ann. Biomed. Eng. Apr 23 [Epub ahead of print] (2009).

• Karim MY, Abbs IC. Mycophenolate mofetil in nonlupus glomerulonephropathy. Lupus 14 Suppl. 1: s39-s41 (2005).

• Katyal M, Tiwari SC, Kumar A, Dinda AK, Arora V, Kumar R, Das N. Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects. Mol. Immunol. 40: 1325-1332 (2004).

• Kau CK, Hu JC, Lu LY, Tseng JC, Wang JS, Cheng HH. Primary Sjogren's syndrome complicated with cryoglobulinemic glomerulonephritis, myocarditis, and multi-organ involvement. J. Formos. Med. Assoc. 103: 707-710 (2004).

• Kaul R, Johnson K, Scholz H, Marr G. Performance of the BioPlex 2200 autoimmune vasculitis kit. Autoimmun. Rev. 8: 224-227 (2009).

• Kazimierczak K, Kopec W, Klinger M. Toll-like receptors (TLR) in the pathogenesis of kidney diseases. Pol. Merkur. Lekarski. 23: 382-385 (2007).

• Kelley VR. Leukocyte-renal epithelial cell interactions regulate lupus nephritis. Semin. Nephrol. 27: 59-68 (2007).

• Kettritz R. Autoimmunity in kidney diseases. Scand. J. Clin. Lab. Invest. Suppl. 241: 99-103 (2008).

• Kevil CG, Hicks MJ, He X, Zhang J, Ballantyne CM, Raman C, Schoeb TR, Bullard DC. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Faslpr mice from autoimmune disease. Am. J. Pathol. 165: 609-616 (2004). *

• Kikuchi S, Santiago-Raber ML, Amano H, Amano E, Fossati-Jimack L, Moll T, Kotzin BL, Izui S. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J. Immunol. 176: 3240-3247 (2006). *

• Kim HA, Chung JW, Park HJ, Joe DY, Yim HE, Park HS, Suh CH. An antinuclear antibody-negative patient with lupus nephritis. Korean J. Intern. Med. 24: 76-79 (2009). *

• Kim J, Choi WS, Kang H, Kim HJ, Suh JH, Sakaguchi S, Kwon B. Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor. J. Immunol. 176: 5223-5331 (2006). *

• Kim J, Choi WS, Kim HJ, Kwon B. Prevention of chronic graft-versus-host disease by stimulation with glucocorticoid-induced TNF receptor. Exp. Mol. Med. 38: 94-99 (2006). *

• Kim J, Park K, Kim HJ, Kim J, Kim HA, Jung D, Kim HJ, Choi HJ, Choi SY, Seo KW, Cho HR, Kwon B. Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment. J. Immunol. 181: 7380-7389 (2008).

• Kim K, Sung YK, Kang CP, Choi CB, Kang C, Bae SC. A regulatory SNP at position -899 in CDKN1A is associated with systemic lupus erythematosus and lupus nephritis. Genes Immun. Mar 5 [Epub ahead of print] (2009).

• Kim YJ, Kim HJ, No JK, Chung HY, Fernandes G. Anti-inflammatory action of dietary fish oil and calorie restriction. Life Sci. 78: 2523-2532 (2006). *

• Kim YJ, Yokozawa T, Chung HY. Suppression of oxidative stress in aging NZB/NZW mice: effect of fish oil feeding on hepatic antioxidant status and guanidino compounds. Free Radic. Res. 39: 1101-1110 (2005).

• Kimmel M, Kuhlmann U, Alscher DM. Pacemaker infection with propionibacterium and a nephritic sediment. Clin. Nephrol. 69: 127-129 (2008).

• Kinoshita K, Ikoma S, Yamagata T, Nozaki Y, Sugiyama M, Funauchi M. Electric charge and sugar chains of immunoglobulin G in systemic lupus erythematosus. Clin. Exp. Nephrol. 10: 25-32 (2006).

• Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, Kanamaru A. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J. Immunol. 173: 5312-5318 (2004). *

• Kinoshita K, Yoo BS, Nozaki Y, Sugiyama M, Ikoma S, Ohno M, Funauchi M, Kanamaru A. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J. Immunol. 170: 5793-5798 (2003). *

• Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 38: 51-62 (1997).

• Kita H. Primary biliary cirrhosis and E. coli-induced pyelonephritis; are infectious agents related to the pathogenesis of primary biliary cirrhosis? Intern. Med. 42: 1063-1064 (2003). *

• Klumb EM, de Andrade MC, Jesus NR, Campani C, Campos CF, Levy RA, Albuquerque E, Cervantes V. Primary antiphospholipid nephropathy beginning during pregnancy. Rheumatol. Int. 27: 289-293 (2007). *

• Kobayashi S, Yoshida M, Kitahara T, Abe Y, Tsuchida A, Nojima Y. Autoimmune pancreatitis as the initial presentation of systemic lupus erythematosus. Lupus 16: 133-136 (2007).

• Kodama T, Imai H, Wakui H, Ohtani H, Komatsuda A, Miura AB. Tubulointerstitial nephritis with renal tubular acidosis and asymptomatic primary biliary cirrhosis accompanied by antibody to a 52-kDa mitochondrial protein alone. Clin. Nephrol. 45: 401-405 (1996).

• Koike K, Utsunomiya Y, Ito Y, Tokudome S, Miyazaki Y, Suzuki T, Okonogi H, Kawamura T, Yamada A, Hosoya T, Joh K. A case of glomerulopathy showing podocytic infolding in association with Sjogren's syndrome and primary biliary cirrhosis. Clin. Exp. Nephrol. 12: 489-493 (2008).

• Kokolina E, Alexopoulos E, Dimitriadis C, Vainas A, Giamalis P, Papagianni A, Ekonomidou D, Memmos D. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Ann. N. Y. Acad. Sci. 1051: 597-605 (2005). *

• Komatsu T, Utsunomiya K, Oyaizu T. Goodpasture's syndrome associated with primary biliary cirrhosis. Intern. Med. 37: 611-613 (1998). *

• Komatsuda A, Ohtani H, Wakui H, Chyzh KA, Hatakeyama T, Iwamoto K, Maki N, Kimura T, Hitomi J, Sawada K. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clin. Nephrol. 66: 315-321 (2006).

• Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. PPARalpha attenuates the proinflammatory response in activated mesangial cells. Am. J. Physiol. Renal Physiol. 296: F328-F336 (2009). *

• Koppang EO, Bjerkas I, Haugarvoll E, Chan EK, Szabo NJ, Ono N, Akikusa B, Jirillo E, Poppe TT, Sveier H, Torud B, Satoh M. Vaccination-induced systemic autoimmunity in farmed atlantic salmon. J. Immunol. 181: 4807-4814 (2008). *

• Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J. Am. Soc. Nephrol. 18: 244-254 (2007). *

• Kornblihtt LI, Vassalllu PS, Heller PG, Lago NR, Alvarez CL, Molinas FC. Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis. Ann. Hematol. 87: 1019-1020 (2008). *

• Kose H, Sado Y, Yamada T, Matsumoto K. Genetic mapping found major QTLs for antibody-induced glomerulonephritis in WKY rats. Exp. Anim. 58: 193-198 (2009).

• Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J. Cardiometab. Syndr. 4: E4-E9 (2009).

• Kourbeti IS, Boumpas DT. Biological therapies of autoimmune diseases. Curr. Drug Targets Inflamm. Allergy 4: 41-46 (2005).

• Kozyro I, Perahud I, Sadallah S, Sukalo A, Titov L, Schifferli J, Trendelenburg M. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics 117: 1663-1668 (2006). *

• Krajewska M, Weyde W, Klinger M. The significance of regulatory CD4+CD25+ T cells in the pathogenesis and treatment of kidney disease. Postepy. Hig. Med. Dosw. (Online) 61: 178-184 (2007).

• Kremer JM, Cannon GW. Benefit/risk of leflunomide in rheumatoid arthritis. Clin. Exp. Rheumatol. 22 (5 Suppl. 35): S95-100 (2004).

• Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front. Biosci. 13: 3312-3320 (2008).

• Kulkarni O, Anders HJ. CCL2/MCP1: a novel target in systemic lupus erythematosus and lupus nephritis. Z. Rheumatol. 67: 220-224 (2008).

• Kulkarni O, Eulberg D, Selve N, Zollner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J. Pharmacol. Exp. Ther. 328: 371-377 (2009). *

• Kurniadhi D, Pujiwati, Wijaya LK, Setiyohadi B, Atmakusuma D. Cerebral thrombosis in systemic lupus erythematosus with the antibody antiphospholipid syndrome. Acta Med. Indones. 39: 82-85 (2007).

• Kuroiwa T, Iwasaki T, Imado T, Sekiguchi M, Fujimoto J, Sano H. Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft-versus-host disease. Arthritis Res. Ther. 8: R123 (2006). *

• Laboudi A, Makdassi R, Cordonnier C, Fournier A, Choukroun G. Chronic interstitial nephritis induced by 5-aminosalicylic acid: a new case report. Nephrologie 23: 343-347 (2002).

• Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J. Gastroenterol. 9: 2300-2307 (2003). *

• Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL.. Extra-intestinal manifestation of IBD in Veszprem county (of Hungary): results of a 25-years follow-up study. Orv. Hetil. 144: 1965-1975 (2003).

• Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 62: 1041-1089 (2002).

• Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin. Nephrol. 64: 73-77 (2005).

• Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front. Biosci. 13: 4984-4992 (2008).

• Langford CA. Update on Wegener granulomatosis. Cleve. Clin. J. Med. 72: 689-690, 693-697 (2005). *

• Lau KK, Jones DP, Ault BH. Prognosis of lupus membranous nephritis in children. Lupus 16: 70 (2007).

• Lau KK, Wyatt RJ. Glomerulonephritis. Adolesc. Med. Clin. 16: 67-85 (2005).

• Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, Lee JY, Huang WQ, Mestecky J, Novak J. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schonlein purpura. Pediatr. Nephrol. 22: 2067-2072 (2007).

• Laura Bertolaccini M, Murru V, Alba P, Khamashta MA. Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al. Arthritis Rheum. 54: 4025-4026 (2006). *

• Laurinavicius A, Gruodyte E, Priluckiene J, Razukeviciene L, Supranaviciene L, Salkus G. Potential causes of antigenemia in the patients with an immune complex-mediated membranoproliferative glomerulonephritis in Lithuania. Medicina (Kaunas) 39 Suppl. 1: 28-32 (2003).

• Lauwerys BR, Wakeland EK. Genetics of lupus nephritis. Lupus 14: 2-12 (2005).

• Lawrence DA, Bolivar VJ, Hudson CA, Mondal TK, Pabello NG. Antibody induction of lupus-like neuropsychiatric manifestations. J. Neuroimmunol. 182: 185-194 (2007).

• Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging 24: 701-715 (2007).

• Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 205: 1879-1888 (2008). *

• Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH. Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatology (Oxford) 42: 1501-1507 (2003). *

• Lee JM, Lee KM, Kim HW, Chung WC, Paik CN, Lee JR, Choi YJ, Yang JM. Crohn's disease in association with IgA nephropathy. Korean J. Gastroenterol. 52: 115-119 (2008).

• Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J, Kellner ES, Nacionales D, Barker T, Kelly-Scumpia K, van Rooijen N, Kumar H, Kawai T, Satoh M, Akira S, Reeves WH. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205: 2995-3006 (2008). *

• Lee Y, Ji J, Song G. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus 18: 727-734 (2009).

• Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis. J. Rheumatol. 33: 698-702 (2006).

• Lenda DM, Stanley ER, Kelley VR. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Faslpr mice. J. Immunol. 173: 4744-4754 (2004). *

• Levine JS, Subang R, Nasr SH, Fournier S, Lajoie G, Wither J, Rauch J. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J. Immunol. 177: 6504-6516 (2006). *

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Lhotta K. Beyond hepatorenal syndrome: glomerulonephritis in patients with liver disease. Semin. Nephrol. 22: 302-308 (2002).

• Li L, Mohan C. Genetic basis of murine lupus nephritis. Semin. Nephrol. 27: 12-21 (2007).

• Li N, Zhao D, Kirschbaum M, Zhang C, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. U.S.A. 105: 4796-4801 (2008). *

• Li QZ, Zhou J, Yang R, Yan M, Ye Q, Liu K, Liu S, Shao X, Li L, Zhou XJ, Wakeland EK, Mohan C. The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun. Mar 5 [Epub ahead of print] (2009).

• Li X. Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine 41: 105-113 (2008).

• Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, Tsokos GC. Phosphorylated ERM Is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178: 1938-1947 (2007). *

• Liapis H, Tsokos GC. Pathology and immunology of lupus glomerulonephritis: can we bridge the two? Int. Urol. Nephrol. 39: 223-231 (2007).

• Lindgren S, Hansen B, Sjoholm AG, Manthorpe R. Complement activation in patients with primary Sjogren's syndrome: an indicator of systemic disease. Autoimmunity 16: 297-300 (1993).

• Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J. Rheumatol. 35: 826-833 (2008).

• Lindqvist AK, Alarcon-Riquelme ME. The genetics of systemic lupus erythematosus. Scand. J. Immunol. 50: 562-571 (1999). *

• Lindqvist AK, Nakken B, Sundler M, Kjellen P, Jonsson R, Holmdahl R, Skarstein K. Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse. Scand. J. Immunol. 61: 119-127 (2005). *

• Lino M, Binaut R, Noel LH, Patey N, Rustin P, Daniel L, Serpaggi J, Varaut A, Vanhille P, Knebelmann B, Grunfeld JP, Fakhouri F. Tubulointerstitial nephritis and Fanconi syndrome in primary biliary cirrhosis. Am. J. Kidney Dis. 46: e41-e46 (2005).

• Lionaki S, Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin. Immunopathol. 29: 459-474 (2007). *

• Lisukov IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, Zonova EV, Chernykh ER, Leplina OY, Sentyakova TN, Demin AA, Kozlov VA. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 13: 89-94 (2004).

• Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D, Nourshargh S, Cook HT, Pusey CD. Experimental autoimmune vasculitis. An animal model of antineutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am. J. Pathol. 174: 1212-1220 (2009).

• Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, Li Z. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J. Immunol. 177: 6880-6888 (2006). *

• Liu K, Li QZ, Yu Y, Liang C, Subramanian S, Zeng Z, Wang HW, Xie C, Zhou XJ, Mohan C, Wakeland EK. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun. 8: 634-645 (2007). *

• Lo SH, Wong KS, Arlt VM, Phillips DH, Lai CK, Poon WT, Chan CK, Mo KL, Chan KW, Chan A. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am. J. Kidney Dis. 45: 407-410 (2005).

• Loh C, Cai YC, Bonventi G, Lajoie G, Macleod R, Wither JE. Dissociation of the genetic loci leading to B1a and NKT cell expansions from autoantibody production and renal disease in B6 mice with an introgressed New Zealand Black chromosome 4 interval. J. Immunol. 178: 1608-1617 (2007). *

• Lorenz HM, Grunke M, Wendler J, Heinzel PA, Kalden JR. Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann. Rheum. Dis. 64: 1517-1519 (2005). *

• Loser K, Balkow S, Higuchi T, Apelt J, Kuhn A, Luger TA, Beissert S. FK506 controls CD40L-induced systemic autoimmunity in mice. J. Invest. Dermatol. 126: 1307-1315 (2006). *

• Louzir B, Othmani S, Ben Abdelhafidh N; Groupe d'Etude du Lupus Erythematuex Systemique en Tunisie. Systemic lupus erythematosus in Tunisia. A multicentric study. About 295 cases. Rev. Med. Interne. 24: 768-774 (2003).

• Lu GY, Guo XF, Wang ZY, Bai X, Su J, Ruan CG. The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 45: 42-44 (2006).

• Lu LY, Cheng HH, Sung PK, Yeh JJ, Shiue YL, Chen A. Single-nucleotide polymorphisms of transforming growth factor-beta1 gene in Taiwanese patients with systemic lupus erythematosus. J. Microbiol. Immunol. Infect. 37: 145-152 (2004). *

• Lu LY, Ding WZ, Fici D, Deulofeut R, Cheng HH, Cheu CC, Sung PK, Schur PH, Fraser PA. Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus in Taiwan. Arthritis Rheum. 40: 1138-1145 (1997).

• Lu X, Kovalev G, Chang H, Kallin E, Knudsen G, Li X, Mishra N, Ruiz P, Li E, Su L, Zhang Y. Inactivation of NuRD component MTA2 causes abnormal T cell activation and lupus-like disease in mice. J. Biol. Chem. 283: 13825-13833 (2008). *

• Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181: 2513-2521 (2008).

• Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr. 93: 327-335 (2004).

• Ludvigsson JF, Montgomery SM, Olen O, Ekbom A, Ludvigsson J, Fored M. Coeliac disease and risk of renal disease - a general population cohort study. Nephrol. Dial. Transplant. 21: 1809-1815 (2006).

• Luo XD, Liu QF, Ning J, Wei YQ, Fan ZP, Zhang Y, Sun J. Clinical analysis of late-onset nephrotic syndrome after allogenic hematopoietic stem cell transplantation. Zhonghua Yi Xue Za Zhi 87: 3280-3283 (2007).

• Lv J, Zhang H, Zhou F, Zou W, Singh AK, Wang H. Antiglomerular basement membrane disease associated with Castleman disease. Am. J. Med. Sci. 337: 206-209 (2009).

• Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 168: 1960-1974 (2006). *

• Ma Z, Chen F, Madaio MP, Cohen PL, Eisenberg RA. Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J. Immunol. 177: 7444-7450 (2006). *

• Macdonald JA, McDonald SP, Hawley CM, Rosman J, Brown F, Wiggins KJ, Bannister K, Johnson DW. Recovery of renal function in end-stage renal failure - comparison between peritoneal dialysis and haemodialysis. Nephrol. Dial. Transplant. May 14 [Epub ahead of print] (2009).

• Macdougall IC, Isles CG, Whitworth JA, More IA, MacSween RN. Interstitial nephritis and primary biliary cirrhosis: a new association? Clin. Nephrol. 27: 36-40 (1987).

• Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlondorff D. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166: 4697-4704 (2001). *

• Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 16: 28-34 (2007).

• Makhlough A, Fakheri H. Membranous glomerulonephritis associated with ulcerative colitis. Iran J. Kidney Dis. 2: 102-104 (2008).

• Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217: 206-221 (2007). *

• Malenica B, Rudolf M, Kozmar A. Antineutrophil cytoplasmic antibodies (ANCA): diagnostic utility and potential role in the pathogenesis of vasculitis. Acta Dermatovenerol. Croat. 12: 294-313 (2004).

• Mamtani M, Rovin B, Brey R, Camargo JF, Kulkarni H, Herrera M, Correa P, Holliday S, Anaya JM, Ahuja SK. CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus. Ann. Rheum. Dis. 67: 1076-1083 (2008).

• Manger K, Repp R, Jansen M, Geisselbrecht M, Wassmuth R, Westerdaal NA, Pfahlberg A, Manger B, Kalden JR, van de Winkel JG. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann. Rheum. Dis. 61: 786-792 (2002). *

• Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, Westerdaal NA, Wentz B, Manger B, Kalden JR, van de Winkel JG. Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum. 41: 1181-1189 (1998). *

• Mani V. Mesalazine-associated interstitial nephritis. Nephrol. Dial. Transplant. 12: 622-623 (1997). *

• Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology. J. Viral Hepat. 4 Suppl. 2: 42-47 (1997).

• Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J. Rare Dis. 1: 6 (2006). *

• Marcus SB, Brown JB, Melin-Aldana H, Strople JA. Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J. Pediatr. Gastroenterol. Nutr. 46: 338-341 (2008). *

• Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J. Clin. Gastroenterol. 32: 176-178 (2001).

• Marín MJ, Garcia I, Pena M, Bolívar A, Zubiaga A, Loez-Hoyos M. E2F1-/- C57BL/6 mice overexpressing a human Bcl-2 transgene in B cells develop a mild autoimmune syndrome. Ann. N. Y. Acad. Sci. 1051: 156-165 (2005). *

• Markel A. Allopurinol-induced DRESS syndrome. Isr. Med. Assoc. J. 7: 656-660 (2005). *

• Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 71: 491-495 (2007). *

• Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr. Nephrol. 22: 77-83 (2007). *

• Marks SD, Tullus K. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date. Paediatr. Drugs 9: 371-378 (2007).

• Martin M. Primary sclerosing cholangitis. Annu. Rev. Med. 44: 221-227 (1993). *

• Martinez A, Orozco G, Varade J, Sanchez Lopez M, Pascual D, Balsa A, Garcia A, de la Concha EG, Fernandez-Gutierrez B, Martin J, Urcelay E. Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum. Immunol. 68: 744-747 (2007).

• Mason LJ, Lambrianides A, Haley JD, Manson JJ, Latchman DS, Isenberg DA, Rahman A. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res. Ther. 7: R971-R983 (2005). *

• Matousovic K, Martinek V. IgA nephropathy. Use of modern laboratory methods and renal biopsy for diagnosis. Vnitr. Lek. 49: 869-873 (2003).

• Matsushita K, Ozaki A, Inoue H, Kaieda T, Akimoto M, Satomura A, Arima N, Hamada H, Suruga Y, Aoki N, Fujiwara H, Tei C. Stevens-Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus. Mod. Rheumatol. 16: 113-116 (2006). *

• Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern. Med. 46: 771-774 (2007). *

• Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat. Clin. Pract. Rheumatol. 2: 252-261 (2006). *

• McDonald J, Fam AG, Paton T, Senn J. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J. Rheumatol. 15: 865-868 (1988).

• McMenamin RA, Davies LM, Craswell PW. Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust. N. Z. J. Med. 6: 583-587 (1976).

• Meiorin SM, Espada G, Costa CE, Tartara A, De Matteo E, Wouters C, Martin TM, Rose CD. Granulomatous nephritis associated with R334Q mutation in NOD2. J. Rheumatol. 34: 1945-1947 (2007).

• Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J. Immunol. 179: 7466-7477 (2007). *

• Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J. Am. Soc. Nephrol. 19: 1177-1189 (2008).

• Meri S. Loss of self-control in the complement system and innate autoreactivity. Ann. N. Y. Acad. Sci. 1109: 93-105 (2007). *

• Merino R, Iwamoto M, Gershwin ME, Izui S. The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB x BXSB)F1 hybrid mice. J. Clin. Invest. 94: 521-525 (1994). *

• Mewar D, Marinou I, Lee ME, Timms JM, Kilding R, Teare MD, Read RC, Wilson AG. Haplotype-specific gene expression profiles in a telomeric major histocompatibility complex gene cluster and susceptibility to autoimmune diseases. Genes Immun. 7: 625-631 (2006). *

• Mihaylova N, Voynova E, Tchorbanov A, Dolashka-Angelova P, Bayry J, Devreese B, Kaveri S, Vassilev T. Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Mol. Immunol. Feb 23 [Epub ahead of print] (2009). *

• Mironiuc A, Comes L, Constantinescu I, Mironiuc C, Bontea D. Cryoglobulinemic vasculitis with multiple digital necrosis in viral hepatitis. Rom. J. Intern. Med. 46: 91-95 (2008).

• Misu N, Zhang M, Mori S, Miyazaki T, Furukawa H, Sasaki T, Nose M, Ono M. Autosomal loci associated with a sex-related difference in the development of autoimmune phenotypes in a lupus model. Eur. J. Immunol. 37: 2787-2796 (2007). *

• Mitoma H, Horiuchi T, Kimoto Y, Tsukamoto H, Uchino A, Tamimoto Y, Miyagi Y, Harada M. Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int. J. Mol. Med. 16: 609-615 (2005).

• Mittal RD, Manchanda PK. Association of interleukin (IL)-4 intron-3 and IL-6 -174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics 59: 159-165 (2007). *

• Miura N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H. Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment. Clin. Nephrol. 71: 74-79 (2009).

• Miyazaki A, Kitaichi N, Ohgami K, Iwata D, Jin XH, Iwabuchi K, Morohashi T, Ohno S, Onoe K. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats. Graefes Arch. Clin. Exp. Ophthalmol. 246: 747-757 (2008).

• Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur. J. Immunol. 35: 1510-1520 (2005). *

• Miyazawa M, Tabata N, Fujisawa R, Hashimoto K, Shiwaku H, Takei YA. Roles of endogenous retroviruses and platelets in the development of vascular injury in spontaneous mouse models of autoimmune diseases. Int. J. Cardiol. 75 Suppl. 1: S65-S73 (2000).

• Mizuno M, Blanchin S, Gasque P, Nishikawa K, Matsuo S. High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am. J. Kidney Dis. 49: 598-606 (2007).

• Mjelle JE, Rekvig OP, Fenton KA. Nucleosomes possess high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis. Ann. Rheum. Dis. 66: 1661-1668 (2007).

• Mok CC. Therapeutic options for resistant lupus nephritis. Semin. Arthritis Rheum. 36: 71-81 (2006). *

• Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 46: 1003-1013 (2002). *

• Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 41: 1090-1095 (1998). *

• Molad Y. Systemic lupus erythematosus and pregnancy. Curr. Opin. Obstet. Gynecol. 18: 613-617 (2006).

• Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71: 1148-1154 (2007). *

• Montano-Loza AJ, Lalor E, Mason AJ. Recognizing immunoglobulin G4 related overlap syndromes in patients with pancreatic and hepatobiliary diseases. Can. J. Gastroenterol. 22: 840-846 (2008).

• Moon BG, Takaki S, Nishizumi H, Yamamoto T, Takatsu K. Abrogation of autoimmune disease in Lyn-deficient mice by the deletion of IL-5 receptor alpha chain gene. Cell. Immunol. 228: 110-118 (2004). *

• Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res. Ther. 8: R182 (2006). *

• Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J. Rheumatol. 32: 740-743 (2005).

• Morel L. Genetics of human lupus nephritis. Semin. Nephrol. 27: 2-11 (2007).

• Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, Wakeland EK. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. U.S.A. 97: 6670-6675 (2000). *

• Morgan MD, Harper L, Williams J, Savage C. Anti-neutrophil cytoplasm-associated glomerulonephritis. J. Am. Soc. Nephrol. 17: 1224-1234 (2006). *

• Morgan PE, Sturgess AD, Hennessy A, Davies MJ. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic. Res. 41: 1301-1312 (2007).

• Morimoto J, Hasegawa Y, Fukushima H, Uesugi N, Hisano S, Saito T, Kaneoka H. Membranoproliferative glomerulonephritis-like glomerular disease and concurrent tubulointerstitial nephritis complicating IgG4-related autoimmune pancreatitis. Intern. Med. 48: 157-162 (2009). *

• Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22: 2531-2539 (2007).

• Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: the central role of nucleosomes revealed. Am. J. Pathol. 172: 275-283 (2008). *

• Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J. Am. Soc. Nephrol. 20: 696-704 (2009).

• Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother. 8: 873-879 (2007).

• Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45: 1497-1504 (2006). *

• Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin. Drug Saf. 6: 99-107 (2007).

• Mountz JD, Yang P, Wu Q, Zhou J, Tousson A, Fitzgerald A, Allen J, Wang X, Cartner S, Grizzle WE, Yi N, Lu L, Williams RW, Hsu HC. Genetic segregation of spontaneous erosive arthritis and generalized autoimmune disease in the BXD2 recombinant inbred strain of mice. Scand. J. Immunol. 61: 128-138 (2005). *

• Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Clin. Immunol. Immunopathol. 72: 162-165 (1994).

• Mubashir E, Ahmed MM, Hayat S, Latif S, Heldmann M, Berney SM. Wegener granulomatosis: a case report and update. South. Med. J. 99: 977-988 (2006).

• Mucenic T, Brenol J, Bredemeier M, Paiva Dos Santos B, Chies J, Monticielo O, Xavier R. Glu298Asp eNOS polymorphism is not associated with SLE. Lupus 18: 448-451 (2009).

• Mukai M. Systemic lupus erythematosus and nucleosome. Nihon Rinsho Meneki Gakkai Kaishi 29: 127-135 (2006).

• Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17: 411-417 (1993).

• Munthe LA, Corthay A, Os A, Zangani M, Bogen B. Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig v region-specific T cells. J. Immunol. 175: 2391-2400 (2005). *

• Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 54: 3591-3600 (2006). *

• Murashima M, Tomaszewski J, Glickman JD. Chronic tubulointerstitial nephritis presenting as multiple renal nodules and pancreatic insufficiency. Am. J. Kidney Dis. 49: e7-e10 (2007).

• Mustafa A, Holladay SD, Goff M, Witonsky SG, Kerr R, Reilly CM, Sponenberg DP, Gogal RM Jr. An enhanced postnatal autoimmune profile in 24 week-old C57BL/6 mice developmentally exposed to TCDD. Toxicol. Appl. Pharmacol. 232: 51-59 (2008). *

• Nakagami H, Tomita N, Kaneda Y, Ogihara T, Morishita R. Anti-oxidant gene therapy by NFkappaB decoy oligodeoxynucleotide. Curr. Pharm. Biotechnol. 7: 95-100 (2006).

• Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur. J. Nucl. Med. Mol. Imaging 34: 2088-2095 (2007).

• Nakajo M, Jinnouchi S, Noguchi M, Uozumi K, Tanabe H, Tateno R, Nakajo M. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin. Nucl. Med. 32: 282-285 (2007).

• Nakamura H, Wada H, Origuchi T, Kawakami A, Taura N, Aramaki T, Fujikawa K, Iwanaga N, Izumi Y, Aratake K, Ida H, Taguchi T, Irie J, Akiyama M, Mizokami A, Tsutsumi T, Eguchi K. A case of IgG4-related autoimmune disease with multiple organ involvement. Scand. J. Rheumatol. 35: 69-71 (2006). *

• Nakamura N, Kumasaka R, Osawa H, Yamabe H, Shirato K, Fujita T, Murakami R, Shimada M, Nakamura M, Okumura K, Hamazaki K, Hamazaki T. Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo 19: 879-882 (2005).

• Nakamura T, Kawagoe Y, Ueda Y, Koide H. Antineutrophil cytoplasmic autoantibody-associated rapidly progressive glomerulonephritis in a patient with primary biliary cirrhosis. Am. J. Med. Sci. 328: 176-179 (2004).

• Nakamura T, Suzuki Y, Koide H. Granulocyte and monocyte adsorption apheresis in a patient with antiglomerular basement membrane glomerulonephritis and active ulcerative colitis. Am. J. Med. Sci. 325: 296-398 (2003).

• Nakashima H. Membranous nephropathy is developed under Th2 environment in chronic graft-versus-host disease. Med. Hypotheses 69: 787-791 (2007).

• Nakashima H, Akahoshi M, Masutani K. Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori 54: 706-713 (2006).

• Nakatani K, Qu WM, Zhang MC, Fujii H, Furukawa H, Miyazaki T, Iwano M, Saito Y, Nose M, Ono M. A genetic locus controlling aging-sensitive regression of B lymphopoiesis in an autoimmune-prone MRL/lpr strain of mice. Scand. J. Immunol. 66: 654-661 (2007). *

• Nakayamada S, Saito K, Nakano K, Tanaka Y. Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum. 56: 1559-1568 (2007). *

• Nakopoulou L, Lazaris AC, Boletis I, Michail S, Iatrou C, Papadakis G, Athanassiadou S, Stathakis C. The expression of matrix metalloproteinase-11 protein in various types of glomerulonephritis. Nephrol. Dial. Transplant. 22: 109-117 (2007).

• Namjou B, Gray-McGuire C, Sestak AL, Gilkeson GS, Jacob CO, Merrill JT, James JA, Wakeland EK, Li QZ, Langefeld CD, Divers J, Ziegler J, Moser KL, Kelly JA, Kaufman KM, Harley JB. Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun. May 14 [Epub ahead of print] (2009).

• Nanda A, Dvorak R, Al-Sabah H, Alsaleh QA. Linear IgA bullous disease of childhood: an experience from Kuwait. Pediatr. Dermatol. 23: 443-447 (2006). *

• Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. 9: 183-191 (2005).

• Nasr SH, Markowitz GS, Goldstein CS, Fildes RD, D'Agati VD. Hereditary nephritis mimicking immune complex-mediated glomerulonephritis. Hum. Pathol. 37: 547-554 (2006).

• Nasr SH, Markowitz GS, Reddy BS, Maesaka J, Swidler MA, D'Agati VD. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int. 69: 772-775 (2006).

• Navarra SV, Saavedra SC, Cayco AV. Renal microtophi in a patient with lupus nephritis and tophaceous gout. J. Clin. Rheumatol. 7: 268-272 (2001).

• Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am. J. Gastroenterol. 98: S18-S23 (2003). *

• Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14: 748-755 (2008). *

• Neumann D, Tschernig T, Popa D, Schmiedl A, de Lema GP, Resch K, Martin MU. Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: synergistic effect on autoimmune symptoms. Int. Immunol. 18: 1779-1787 (2006). *

• Nguyen V, Cudrici C, Zernetkina V, Niculescu F, Rus H, Drachenberg C, Rus V. TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. Clin. Immunol. Apr 4 [Epub ahead of print] (2009). *

• Nieradko-Iwanicka B, Majdan M, Piotrowski M, Radwan P, Kwiatkowski P. Association of ulcerative colitis and lupus nephropathy - report of two cases. Pol. Arch. Med. Wewn. 115: 559-564 (2006).

• Nikolov NP, Smith JA, Patronas NJ, Illei GG. Diagnosis and treatment of vasculitis of the central nervous system in a patient with systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 627-633 (2006). *

• Nishi H, Tojo A, Onozato ML, Jimbo R, Nangaku M, Uozaki H, Hirano K, Isayama H, Omata M, Kaname S, Fujita T. Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis. Nephrol. Dial. Transplant. 22: 1273-1275 (2007).

• Nishie T, Miyaishi O, Azuma H, Kameyama A, Naruse C, Hashimoto N, Yokoyama H, Narimatsu H, Wada T, Asano M. Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice. Am. J. Pathol. 170: 447-456 (2007). *

• Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 24: 1249-1254 (1994).

• Nishimura H, Strominger JL. Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 103: 3292-3297 (2006). *

• Nitzan O, Elias M, Saliba WR. Systemic lupus erythematosus and inflammatory bowel disease. Eur. J. Intern. Med. 17: 313-318 (2006).

• Njoku CJ, Patrick KS, Ruiz P Jr, Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J. Investig. Med. 53: 347-352 (2005).

• Nochy D, Lefaucheur C, Bariety J. Renal biopsy: methods. Nephrol. Ther. May 15 [Epub ahead of print] (2009).

• Noel LH. Antineutrophil cytoplasm antibodies (ANCA): description and immunopathological role. Ann. Med. Interne (Paris) 151: 178-183 (2000).

• Nogaki F, Oida E, Kamata T, Kobayashi I, Nomura K, Suyama K, Tahara S, Ono T, Miyawaki S, Serikawa T, Yoshida H, Kita T, Muso E. Chromosomal mapping of hyperserum IgA and glomerular IgA deposition in a high IgA (HIGA) strain of DdY mice. Kidney Int. 68: 2517-2525 (2005). *

• Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J. Autoimmun. 16: 275-285 (2001). *

• Obermeier F, Hausmann M, Kellermeier S, Kiessling S, Strauch UG, Duitman E, Bulfone-Paus S, Herfarth H, Bock J, Dunger N, Stoeck M, Scholmerich J, Falk W, Rogler G. IL-15 protects intestinal epithelial cells. Eur. J. Immunol. 36: 2691-2699 (2006). *

• Odegard JM, DiPlacido LD, Greenwald L, Kashgarian M, Kono DH, Dong C, Flavell RA, Craft J. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J. Immunol. 182: 4076-4084 (2009).

• Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod. Rheumatol. 17: 92-97 (2007). *

• Ohara T, Kanoh Y, Taguma Y, Hashimoto H, Suzuki H, Sakai Y, Kondo F, Kameyama J, Tani N, Yoshino K, Kitajima M. High incidence of Dieulafoy's lesions in upper gastrointestinal bleeding associated with polyarteritis - clinical examination of patients of polyarteritis nodosa with rapidly progressive glomerulonephritis. Hepatogastroenterology 55: 821-825 (2008).

• Ohba K, Omagari K, Murase K, Hazama H, Masuda J, Kinoshita H, Isomoto H, Mizuta Y, Miyazaki M, Murata I, Kohno S. A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice. Pathology 34: 250-256 (2002). *

• Ohkawara T, Nishihira J, Takeda H, Asaka M, Sugiyama T. Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J. Gastroenterol. 40: 117-122 (2005). *

• Ohno N, Ota Y, Hatakeyama S, Yanagimoto S, Morisawa Y, Tsukada K, Koike K, Kimura S. A patient with E. coli-induced pyelonephritis and sepsis who transiently exhibited symptoms associated with primary biliary cirrhosis. Intern. Med. 42: 1144-1148 (2003). *

• Ohsawa M. Heavy metal-induced immunotoxicity and its mechanisms. Yakugaku Zasshi 129: 305-319 (2009).

• Ohya M, Otani H, Kimura K, Kodama N, Minami Y, Liang XM, Maeshima E, Yamada Y, Mune M, Yukawa S. Interstitial nephritis induced by mesalazine. Nippon Jinzo Gakkai Shi. 44: 414-419 (2002).

• Okada H, Inoue T, Hashimoto K, Suzuki H, Matsushita S. D1-like receptor antagonist inhibits IL-17 expression and attenuates crescent formation in nephrotoxic serum nephritis. Am. J. Nephrol. 30: 274-279 (2009).

• Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14: 779-782 (2002).

• Olowu W. Childhood-onset systemic lupus erythematosus. J. Natl. Med. Assoc. 99: 777-784 (2007). *

• Onel K, Huo D, Hastings D, Fryer-Biggs J, Crow M, Onel K. Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults. Lupus 18: 61-66 (2009).

• Ooi JD, Holdsworth SR, Kitching AR. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J. Autoimmun. 31: 295-300 (2008).

• Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J. Am. Soc. Nephrol. 20: 980-989 (2009).

• Orozco G, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA. Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schonlein purpura. Clin. Exp. Rheumatol. 25: 750-753 (2007).

• Orozco G, Sanchez E, Gomez LM, Gonzalez-Gay MA, Lopez-Nevot MA, Torres B, Ortego-Centeno N, Jimenez-Alonso J, de Ramon E, Sanchez-Roman E, Anaya JM, Sturfelt G, Gunnarsson I, Alarcon-Riquelme M, Gonzalez-Escribano MF, Svennugsson E, Martin J. Study of the role of functional variants of SLC22A4, RUNX1 and SUMO4 in systemic lupus erythematosus. Ann. Rheum. Dis. 65: 791-795 (2006). *

• Ostergaard PA, Eriksen J. Association between HLA-A1,B8 in children with extrinsic asthma and IgA deficiency. Eur. J. Pediatr. 131: 263-270 (1979).

• Otukesh H, Chalian M, Hoseini R, Chalian H, Hooman N, Bedayat A, Yazdi RS, Sabaghi S, Mahdavi S. Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin. Rheumatol. 26: 2105-2107 (2007). *

• Ou TT, Tsai WC, Chen CJ, Chang JG, Yen JH, Wang WS, Lin CH, Tsai JJ, Liu HW. Genetic analysis of interleukin-10 promoter region in patients with systemic lupus erythematosus in Taiwan. Kaohsiung J. Med. Sci. 14: 599-606 (1998).

• Ozaki Y, Nomura S, Nagahama M, Yoshimura C, Kagawa H, Fukuhara S. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron 85: 86-91 (2000).

• Pablos JL, Carreira PE, Martin-Villa JM, Montalvo G, Arnaiz-Villena A, Gomez-Reino JJ. Polymorphism of the heat-shock protein gene HSP70-2 in systemic lupus erythematosus. Br. J. Rheumatol. 34: 721-723 (1995).

• Pagnoux C. Wegener's granulomatosis and microscopic polyangiitis. Rev. Prat. 58: 522-532 (2008).

• Palazzi C, D'Amico E, Cacciatore P, Pennese E, Olivieri I. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema. Clin. Rheumatol. 24: 632-633 (2005). *

• Palma BD, Gabriel Jr A, Colugnati FA, Tufik S. Effects of sleep deprivation on the development of autoimmune disease in an experimental model of systemic lupus erythematosus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291: R1527-R1532 (2006). *

• Pals ST, Radaszkiewicz T, Roozendaal L, Gleichmann E. Chronic progressive polyarthritis and other symptoms of collagen vascular disease induced by graft-vs-host reaction. J. Immunol. 134: 1475-1482 (1985).

• Pan C, Wu C, Chen H, Dang C, Chang F, Liu H, Chu C, Lin M, Lee Y. Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan. Lupus 18: 698-704 (2009).

• Panzer U, Steinmetz OM, Paust HJ, Meyer-Schwesinger C, Peters A, Turner JE, Zahner G, Heymann F, Kurts C, Hopfer H, Helmchen U, Haag F, Schneider A, Stahl RA. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 18: 2071-2084 (2007). *

• Pao LI, Lam KP, Henderson JM, Kutok JL, Alimzhanov M, Nitschke L, Thomas ML, Neel BG, Rajewsky K. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27: 35-48 (2007). *

• Parambil JG, Keogh KA, Fervenza FC, Ryu JH. Microscopic polyangiitis associated with thymoma, exacerbating after thymectomy. Am. J. Kidney Dis. 48: 827-831 (2006).

• Parsa A, Lovett DH, Peden EA, Zhu L, Seldin MF, Criswell LA. Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun. 6: 217-224 (2005). *

• Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can. J. Gastroenterol. 23: 170-176 (2009).

• Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 54: 2963-2969 (2006). *

• Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, Klassen J, Cattran D, St George-Hyslop P, Pei Y. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J. Am. Soc. Nephrol. 18: 2408-2415 (2007). *

• Patole PS, Pawar RD, Lech M, Zecher D, Schmidt H, Segerer S, Ellwart A, Henger A, Kretzler M, Anders HJ. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol. Dial. Transplant. 21: 3062-3073 (2006).

• Patole PS, Pawar RD, Lichtnekert J, Lech M, Kulkarni OP, Ramanjaneyulu A, Segerer S, Anders HJ. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J. Autoimmun. 29: 52-59 (2007).

• Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, Holscher C, Wolf G, Kurts C, Mittrucker HW, Stahl RA, Panzer U. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20: 969-979 (2009).

• Pawar RD, Castrezana-Lopez L, Allam R, Kulkarni OP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Grone HJ, Anders HJ. Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology Oct 24 [Epub ahead of print] (2008).

• Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ. Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J. Am. Soc. Nephrol. 17: 3365-3373 (2006). *

• Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D, Anders HJ. Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 17: 141-149 (2006). *

• Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18: 1721-1731 (2007). *

• Pecorella I, La Cava M, Mannino G, Pinca M, Pezzi PP. Diffuse granulomatous necrotizing scleritis. Acta Ophthalmol. Scand. 84: 263-265 (2006). *

• Perez de Lema G, Lucio-Cazana FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano V, Banas B, Mampaso F, Schlondorff D. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int. 66: 1018-1028 (2004). *

• Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin. Drug Saf. 6: 183-190 (2007).

• Pfau JC, Sentissi JJ, Li S, Calderon-Garciduenas L, Brown JM, Blake DJ. Asbestos-induced autoimmunity in C57BL/6 mice. J. Immunotoxicol. 5: 129-137 (2008).

• Phoon RK, Kitching AR, Odobasic D, Jones LK, Semple TJ, Holdsworth SR. T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 19: 477-485 (2008). *

• Pilones K, Lai ZW, Gavalchin J. Prenatal HgCl(2) exposure alters fetal cell phenotypes. J. Immunotoxicol. 4: 295-301 (2007).

• Pisoni CN, Karim Y, Cuadrado MJ. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14 Suppl. 1: s9-s11 (2005).

• Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56: 1894-1903 (2007). *

• Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol. 62: 49-53 (2004).

• Polzer K, Soleiman A, Baum W, Axmann R, Distler J, Redlich K, Kilian A, Kronke G, Schett G, Zwerina J. Selective p38MAPK isoform expression and activation in ANCA-associated crescentic glomerulonephritis: role of p38MAPK alpha. Ann. Rheum. Dis. 67: 602-608 (2008).

• Ponniah I, Shaheen A, Shankar KA, Kumaran MG. Wegener's granulomatosis: the current understanding. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100: 265-270 (2005).

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Potlukova E, Jiskra J, Limanova Z, Kralikova P, Smutek D, Mareckova H, Antosova M, Trendelenburg M. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin. Exp. Immunol. 153: 96-101 (2008). *

• Potlukova E, Kralikova P. Complement component C1q and anti-C1q antibodies in theory and in clinical practice. Scand. J. Immunol. 67: 423-430 (2008). *

• Pradhan VD, Badakere SS, Bichile LS, Almeida AF. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J. Assoc. Physicians India 52: 533-537 (2004).

• Pradhan VD, Badakere SS, Iyer YS, Kumar R, Almeida AF. A study of anti-neutrophil cytoplasm antibodies in systemic vasculitis and other related disorders. J. Postgrad. Med. 49: 5-9 (2003). *

• Pradhan VD, Badakere SS, Pawar AR, Almeida AF. Anti-myeloperoxidase antibodies in patients with microscopic polyangiitis. Indian J. Med. Sci. 57: 479-486 (2003).

• Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bombardieri S, Migliorini P. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J. Rheumatol. 27: 109-115 (2000).

• Presti ME, Neuschwander-Tetri BA, Vogler CA, Janney CG, Roche JK. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. Dig. Dis. Sci. 42: 813-816 (1997). *

• Principi M, Di Leo A, Ingrosso M, Pisani A, Marangi S, Amoruso A, Panella C, Francavilla A, Ierardi E. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol. Immunotoxicol. 26: 243-248 (2004).

• Qian SX, Li JY, Hong M, Xu W, Qiu HX. Nonhematological autoimmunity (glomerulosclerosis, paraneoplastic pemphigus and paraneoplastic neurological syndrome) in a patient with chronic lymphocytic leukemia: Diagnosis, prognosis and management. Leuk. Res. 33: 500-505 (2009).

• Qian Y, Giltiay N, Xiao J, Wang Y, Tian J, Han S, Scott M, Carter R, Jorgensen TN, Li X. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur. J. Immunol. 38: 2219-2228 (2008). *

• Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford) 44: 1108-1114 (2005). *

• Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 38: 93-103 (2005).

• Ragnarsdottir B, Fischer H, Godaly G, Gronberg-Hernandez J, Gustafsson M, Karpman D, Lundstedt AC, Lutay N, Ramisch S, Svensson ML, Wullt B, Yadav M, Svanborg C. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur. J. Clin. Invest. 38 Suppl. 2: 12-20 (2008).

• Ramaswami A, Kandaswamy T, Rajendran T, Jeyakrishnan KP, Aung H, Iqbal M, Jacob CK, Zinna HS, Kafeel G. Scleroderma with crescentic glomerulonephritis: a case report. J. Med. Case Reports 2: 151 (2008). *

• Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, Santiuste-Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 16: 775-781 (2007).

• Ramos-Casals M, Brito-Zeron P, Soria N, Nardi N, Vargas A, Munoz S, Bove A, Suarez B, Lozano F. Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjogren's syndrome. Rheumatology (Oxford) 48: 65-69 (2009). *

• Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536-539 (2002). *

• Reaves TA, Chin AC, Parkos CA. Neutrophil transepithelial migration: role of Toll-like receptors in mucosal inflammation. Mem. Inst. Oswaldo Cruz 100: 191-198 (2005). *

• Reichlin M. Autoantibodies to the ribosomal P proteins in systemic lupus erythematosus. Clin. Exp. Med. 6: 49-52 (2006). *

• Reilly CM, Olgun S, Goodwin D, Gogal RM Jr, Santo A, Romesburg JW, Ansar Ahmed S, Gilkeson GS. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur. J. Immunol. 36: 1296-1308 (2006). *

• Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Gueguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P. Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum. 54: 2523-2532 (2006). *

• Revert F, Merino R, Monteagudo C, Macias J, Peydro A, Alcacer J, Muniesa P, Marquina R, Blanco M, Iglesias M, Revert-Ros F, Merino J, Saus J. Increased goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basement membrane. Am. J. Pathol. 171: 1419-1430 (2007). *

• Reynolds J, Abbott DS, Karegli J, Evans DJ, Pusey CD. Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis. Am. J. Pathol. 174: 2202-2210 (2009). *

• Reynolds J, Haxby J, Juggapah JK, Evans DJ, Pusey CD. Identification of a nephritogenic immunodominant B and T cell epitope in experimental autoimmune glomerulonephritis. Clin. Exp. Immunol. 155: 311-319 (2009). *

• Reynolds J, Khan SB, Allen AR, Benjamin CD, Pusey CD. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int. 66: 1444-1452 (2004).

• Reynolds J, Norgan VA, Bhambra U, Smith J, Cook HT, Pusey CD. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. 13: 359-369 (2002). *

• Reynolds J, Prodromidi EI, Juggapah JK, Abbott DS, Holthaus KA, Kalluri R, Pusey CD. Nasal administration of recombinant rat alpha3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J. Am. Soc. Nephrol. 16: 1350-1359 (2005). *

• Ridder RM, Kreth HW, Kiss E, Grone HJ, Gordjani N. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr. Nephrol. 20: 1349-1351 (2005). *

• Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V. Treatment of lupus nephritis with cyclosporine - an outcome analysis. Kidney Blood Press. Res. 30: 124-128 (2007).

• Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, Kim MY, Fischer J, Clancy RM, Buyon JP. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann. Rheum. Dis. 68: 828-835 (2009).

• Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr. Drug Targets 10: 26-37 (2009).

• Robak E, Sysa-Jedrzejowska A, Wozniacka A. Progress and perspectives in the treatment of systemic lupus erythematosus. Przegl. Lek. 62: 894-899 (2005).

• Roberts-Thomson PJ, Roberts-Thomson RA, Nikoloutsopoulos T, Gillis D. Immune dysfunction in Australian Aborigines. Asian Pac. J. Allergy Immunol. 23: 235-244 (2005).

• Robertson J, Wu J, Arends J, Zhou C, Adrogue HE, Chan JT, Lou Y. Spontaneous recovery from early glomerular inflammation is associated with resistance to anti-GBM glomerulonephritis: tolerance and autoimmune tissue injury. J. Autoimmun. 30: 246-256 (2008).

• Robertson MB, Choe KA, Joseph PM. Review of the abdominal manifestations of cystic fibrosis in the adult patient. Radiographics 26: 679-690 (2006). *

• Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum. 52: 642-650 (2005). *

• Romas E, Power DA, Machet D, Powell H, d'Apice AJ. Membranous glomerulonephritis associated with hepatitis C virus infection in an adolescent. Pathology 26: 399-402 (1994).

• Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun. Rev. 7: 235-239 (2008).

• Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13: 904-922 (2008).

• Rovin BH, Lu L, Zhang X. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int. 62: 261-265 (2002). *

• Rozenkov V. Antineutrophil Cytoplasmic Antibodies (ANCA): Pathophysiological aspects, investigation opportunities and diagnostic role. THE CANBERRA HOSPITAL, AUSTRALIA: PATHOLOGY NEWSLETTER NUMBER 53 p. 4-11 (2000). *

• Rubin Kelley V. Lupus nephritis: introduction. Semin. Nephrol. 27: 1 (2007).

• Russinko PJ, Agarwal S, Choi MJ, Kelty PJ. Obstructive nephropathy secondary to sulfasalazine calculi. Urology 62: 748 (2003).

• Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance. Transplantation 84: S26-S30 (2007).

• Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin. Exp. Rheumatol. 21 (6 Suppl. 32): S55-S63 (2003).

• Ryan MJ. Water and Electrolyte Homeostasis Section Young Investigator Award Lecture. The pathophysiology of hypertension in systemic lupus erythematosus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R1258-R1267 (2009). *

• Ryan MJ, McLemore Jr GR, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48: 988-993 (2006).

• Sabry A, Elbasyouni SR, Sheashaa HA, Alhusseini AA, Mahmoud K, George SK, Kaleek EA, Abo-Zena H, Kalil AM, Mohsen T, Rahim MA, El-Samanody AZ. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int. Urol. Nephrol. 38: 731-737 (2006).

• Sabry A, Sheashaa H, El-Husseini A, El-Dahshan K, Abdel-Rahim M, Elbasyouni SR. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis. Clin. Rheumatol. 26: 1819-1823 (2007). *

• Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus. Nephrology (Carlton) 11: 329-335 (2006). *

• Sadanaga A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T, Sugiyama N, Niiro H, Harada M. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum. 56: 1618-1628 (2007). *

• Saeki T, Imai N, Ito T, Yamazaki H, Nishi S. Membranous nephropathy associated with IgG4-related systemic disease and without autoimmune pancreatitis. Clin. Nephrol. 71: 173-178 (2009).

• Saeki T, Saito A, Yamazaki H, Emura I, Imai N, Ueno M, Nishi S, Miyamura S, Gejyo F. Tubulointerstitial nephritis associated with IgG4-related systemic disease. Clin. Exp. Nephrol. 11: 168-173 (2007).

• Saga D, Sakatsume M, Ogawa A, Tsubata Y, Kaneko Y, Kuroda T, Sato F, Ajiro J, Kondo D, Miida T, Narita I, Gejyo F. Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis. Kidney Int. 67: 1821-1829 (2005). *

• Sahay R, Prangnell DR, Scott BB. Inflammatory bowel disease and refractory anaemia (myelodysplasia). Gut 34: 1630-1631 (1993). *

• Saint Marcoux B, De Bandt M; on behalf of the CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73: 710-713 (2006). *

• Sakaguchi Y, Inaba M, Tsuda M, Quan GK, Omae M, Ando Y, Uchida K, Okazaki K, Ikehara S. The Wistar Bonn Kobori rat, a unique animal model for autoimmune pancreatitis with extrapancreatic exocrinopathy. Clin. Exp. Immunol. 152: 1-12 (2008). *

• Salama AD, Pusey CD. Shining a LAMP on pauci-immune focal segmental glomerulonephritis. Kidney Int. 76: 15-17 (2009). *

• Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann. Hepatol. 6: 186-189 (2007). *

• Salizzoni M, Gennari F, Liddo G, Mirabella S, Brunati A, Strignano P, Cerutti E. Sequential liver-kidney transplantation. Transplant. Proc. 36: 543-544 (2004). *

• Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Ann. Rheum. Dis. 63: 1250-1254 (2004). *

• Sanchez E, Callejas-Rubio JL, Sabio JM, Gonzalez-Gay MA, Jimenez-Alonso J, Mico L, de Ramon E, Camps M, Suarez A, Gutierrez C, Garcia-Portales R, Tolosa C, Ortego-Centeno N, Sanchez-Roman J, Garcia-Hernandez FJ, Gonzalez-Escribano MF, Martin J. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus. Clin. Exp. Rheumatol. 27: 267-271 (2009).

• Sanchez E, Morales S, Paco L, Lopez-Nevot MA, Hidalgo C, Jimenez-Alonso J, Torres B, Gonzalez-Gay MA, Callejas JL, Ortego-Centeno N, Sanchez-Roman J, Gonzalez-Escribano MF, Martin J. Interleukin 12 (IL12B), interleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A) gene polymorphism in systemic lupus erythematosus. Rheumatology (Oxford) 44: 1136-1139 (2005). *

• Sano F, Ozawa R, Machida H, Miyamae T, Ito S, Imagawa T, Mori M, Okuyama K, Yokota S. Two female siblings with childhood-onset systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi 31: 172-177 (2008).

• Sansonno L, Tucci FA, Sansonno S, Lauletta G, Troiani L, Sansonno D. B cells and HCV: an infection model of autoimmunity. Autoimmun. Rev. Mar 21 [Epub ahead of print] (2009).

• Santiago-Raber ML, Kikuchi S, Borel P, Uematsu S, Akira S, Kotzin BL, Izui S. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J. Immunol. 181: 1556-1562 (2008).

• Santoro D, Stella M, Montalto G, Castellino S. Lupus nephritis after hepatitis B vaccination: an uncommon complication. Clin. Nephrol. 67: 61-63 (2007).

• Sanz AB, Moreno JA, Sanchez-Nino MD, Ucero AC, Benito A, Santamaria B, Justo P, Izquierdo MC, Egido J, Blanco-Colio LM, Ortiz A. TWEAKing renal injury. Front. Biosci. 13: 580-589 (2008).

• Sardjono CT, Mottram PL, Velde NC, Powell MS, Power D, Slocombe RF, Wicks IP, Campbell IK, McKenzie SE, Brooks M, Stevenson AW, Hogarth PM. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum. 52: 3220-3229 (2005). *

• Sari I, Birlik M, Cavdar C, Sarioglu S, Akpinar H, Onen F, Akkoc N. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy. N. Z. Med. J. 118: U1662 (2005).

• Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 56: 631-638 (2007). *

• Sarraf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev. Mol. Med. 7: 1-19 (2005).

• Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin. Pract. 108: c194-c201 (2008).

• Sato T, Ishikawa S, Akadegawa K, Ito T, Yurino H, Kitabatake M, Yoneyama H, Matsushima K. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 34: 3346-3358 (2004). *

• Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, Gorden P, Raymond-Barker P, Murgatroyd PR, Adams C, Scobie I, Mufti GJ, Alexander GJ, Thiru S, Murano I, Cinti S, Chaudhry AN, Smith KG, O'Rahilly S. Complement abnormalities in acquired lipodystrophy revisited. J. Clin. Endocrinol. Metab. 94: 10-16 (2009). *

• Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, Krug A. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58: 1107-1115 (2008). *

• Savige JA, Chang L, Wilson D, Buchanan RR. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol. Int. 16: 109-114 (1996).

• Savige JA, Davies DJ, Gatenby PA. Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report from workshops. Pathology 26: 186-193 (1994). *

• Savino MT, Ortensi B, Ferro M, Ulivieri C, Fanigliulo D, Paccagnini E, Lazzi S, Osti D, Pelicci G, Baldari CT. Rai acts as a negative regulator of autoimmunity by inhibiting antigen receptor signaling and lymphocyte activation. J. Immunol. 182: 301-308 (2009).

• Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100: 1362-1369 (2005). *

• Schafer R, Sheil JM. Superantigens and their role in infectious disease. Adv. Pediatr. Infect. Dis. 10: 369-390 (1995).

• Schedel J, Mayer S, Woenckhaus M, Kiss E, Scholmerich J, Rogler G. Autoimmune cholangitis with vasculitic ulcers, rheumatoid arthritis and IgA glomerulonephritis. Dtsch. Med. Wochenschr. 129: 2409-2412 (2004).

• Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Karre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126: 140-146 (2009). *

• Schnabel A, Hauschild S, Gross WL. Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Int. Arch. Allergy Immunol. 109: 201-206 (1996).

• Schneider M. Exploring new territory: considering the future. Lupus 16: 221-226 (2007).

• Schultz DR, Tozman EC. Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Semin. Arthritis Rheum. 25: 143-159 (1995). *

• Schwarting A. Genetic predisposition - is lupus nephritis a question of copy numbers? Nephrol. Dial. Transplant. 21: 2378-2379 (2006).

• Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16: 3264-3272 (2005). *

• Schwartz MM. The pathology of lupus nephritis. Semin. Nephrol. 27: 22-34 (2007).

• Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27: 242-250 (2006).

• Seelen MA, Trouw LA, van der Hoorn JW, Fallaux-van den Houten FC, Huizinga TW, Daha MR, Roos A. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin. Exp. Immunol. 134: 335-343 (2003). *

• Segerer S, Henger A, Schmid H, Kretzler M, Draganovici D, Brandt U, Noessner E, Nelson PJ, Kerjaschki D, Schlondorff D, Regele H. Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int. 69: 1765-1773 (2006). *

• Sepe V, Libetta C, Giuliano MG, Adamo G, Dal Canton A. Mycophenolate mofetil in primary glomerulopathies. Kidney Int. 73: 154-162 (2008). *

• Seredkina N, Zykova SN, Rekvig OP. Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to up-regulated apoptosis. Am. J. Pathol. Jun 15 [Epub ahead of print] (2009).

• Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch. Pathol. Lab. Med. 133: 233-248 (2009).

• Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52: 501-513 (2005). *

• Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123: 66-73 (2007). *

• Shaer AJ, Stewart LR, Cheek DE, Hurray D, Self SE. IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am. J. Kidney Dis. 41: 1097-1109 (2003).

• Shah P, Tramontano A, Makker SP. Intramolecular epitope spreading in Heymann nephritis. J. Am. Soc. Nephrol. 18: 3060-3066 (2007). *

• Shalev I, Liu H, Koscik C, Bartczak A, Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, Winter E, Manuel J, McCarthy D, Cattral M, Gommerman J, Clark DA, Phillips MJ, Gorczynski RR, Zhang L, Downey G, Grant D, Cybulsky MI, Levy G. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J. Immunol. 180: 249-260 (2008). *

• Shen L, Zhang C, Wang T, Brooks S, Ford RJ, Lin-Lee YC, Kasianowicz A, Kumar V, Martin L, Liang P, Cowell J, Ambrus JL Jr. Development of autoimmunity in IL-14alpha-transgenic mice. J. Immunol. 177: 5676-5686 (2006). *

• Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun. Rev. 5: 153-155 (2006).

• Shi Y, Pestka JJ. Attenuation of mycotoxin-induced IgA nephropathy by eicosapentaenoic acid in the mouse: dose response and relation to IL-6 expression. J. Nutr. Biochem. 17: 697-706 (2006). *

• Shim GJ, Warner M, Kim HJ, Andersson S, Liu L, Ekman J, Imamov O, Jones ME, Simpson ER, Gustafsson JA. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc. Natl. Acad. Sci. U.S.A. 101: 12628-12633 (2004). *

• Shimazaki K, Jirawuthiworavong GV, Nguyen EV, Awazu M, Levinson RD, Gordon LK. Tubulointerstitial nephritis and uveitis syndrome: a case with an autoimmune reactivity against retinal and renal antigens. Ocul. Immunol. Inflamm. 16: 51-53 (2008).

• Shimohata H, Yamada A, Yoh K, Ishizaki K, Morito N, Yamagata K, Takahashi S. Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background. J. Nephrol. 22: 123-129 (2009).

• Shimomura H. Studies on anti-LP-1 and anti-Tamm-Horsfall glycoprotein in chronic liver disease using ADCC assay against antigen-coated target cells. Acta Med. Okayama 36: 361-370 (1982).

• Shin HD, Park BL, Cheong HS, Lee HS, Jun JB, Bae SC. DNase II polymorphisms associated with risk of renal disorder among systemic lupus erythematosus patients. J. Hum. Genet. 50: 107-111 (2005). *

• Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38: 123-137 (2005).

• Short KA, Kalu G, Mortimer PS, Higgins EM. Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa. Clin. Exp. Dermatol. 30: 481-483 (2005).

• Showkat A, Lo A, Shokouh-Amiri H, Nezakatgoo N, Gaber AO, Mya M, Egidi MF. Are autoimmune diseases or glomerulonephritis affecting the development of panel-reactive antibodies in candidates for renal transplantation? Transplant. Proc. 37: 645-647 (2005). *

• Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391-397 (2004).

• Siedner MJ, Christopher-Stine L, Astor BC, Gelber AC, Fine DM. Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists. J. Rheumatol. 34: 973-977 (2007).

• Silver KL, Crockford TL, Bouriez-Jones T, Milling S, Lambe T, Cornall RJ. MyD88-dependent autoimmune disease in Lyn-deficient mice. Eur. J. Immunol. 37: 2734-2743 (2007). *

• Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J. Immunol. 180: 2069-2080 (2008). *

• Singh S, Devidayal, Minz R, Nada R, Joshi K. Childhood lupus nephritis: 12 years experience from North India. Rheumatol. Int. 26: 604-607 (2006). *

• Singri N, Gleason B, Flamm SL, Kanwar YS, Ghossein C. Secondary IgA nephropathy presenting as nephrotic syndrome with glomerular crescentic changes and acute renal failure in a patient with autoimmune hepatitis. J. Nephrol. 17: 125-129 (2004).

• Sinha A, Bagga A. Pulse steroid therapy. Indian J. Pediatr. 75: 1057-1066 (2008).

• Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G, Bollini B, Li Vecchi M. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann. N. Y. Acad. Sci. 1050: 193-200 (2005). *

• Sireci G, Russo D, Dieli F, Porcelli SA, Taniguchi M, La Manna MP, Di Liberto D, Scarpa F, Salerno A. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur. J. Immunol. 37: 425-433 (2007). *

• Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, Testi A, Plaza J, Sentis J, Coca A. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17: 281-288 (2008).

• Siveke JT, Egert J, Sitter T, Schiemann U, Walcher P, Torok HP, Glas J, Folwaczny C. 5-ASA therapy and renal function in inflammatory bowel disease. Am. J. Gastroenterol. 100: 501 (2005). *

• Sixdorf U, Bauer H, Marker-Hermann E. Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil. Dtsch. Med. Wochenschr. 131: 2266-2269 (2006).

• Skalova S, Dedek P, Pozler O, Podhola M. Mesalazine-induced interstitial nephritis. Ren. Fail. 31: 159-161 (2009).

• Skalova S, Minxova L, Slezak R. Hypokalaemic paralysis revealing Sjogren's syndrome in a 16-year old girl. Ghana Med. J. 42: 124-128 (2008). *

• Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine 26 Suppl. 8: I9-I14 (2008).

• Skopouli FN, Moutsopoulos HM. Autoimmune epitheliitis: Sjogren's syndrome. Clin. Exp. Rheumatol. 12 Suppl. 11: S9-S11 (1994).

• Sleasman JW. The association between immunodeficiency and the development of autoimmune disease. Adv. Dent. Res. 10: 57-61 (1996). *

• Slot M, Theunissen R, Van Paassen P, Damoiseaux J, Cohen Tervaert JW. Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study. J. Autoimmune Dis. 3: 4 (2006). *

• Smilde TJ, van Liebergen FJ, Koolen MI, Gerlag PG, Assmann KJ, Berden JH. Tubulointerstitial nephritis caused by mesalazine (5-ASA) agents. Ned. Tijdschr. Geneeskd. 138: 2557-2561 (1994).

• Smith DL, Dong X, Du S, Oh M, Singh RR, Voskuhl RR. A female preponderance for chemically induced lupus in SJL/J mice. Clin. Immunol. 122: 101-107 (2007). *

• Smith KD. Lupus nephritis: Toll the trigger! J. Am. Soc. Nephrol. 17: 3273-3275 (2006). *

• Smith KD. Toll-like receptors in kidney disease. Curr. Opin. Nephrol. Hypertens. 18: 189-196 (2009).

• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54: 2970-2982 (2006). *

• Smykal-Jankowiak K, Niemir ZI. Structure and function of complement protein C1q and its role in the development of autoimmune diseases. Postepy. Hig. Med. Dosw. (Online) 63: 134-141 (2009).

• Soehardy Z, Hayati SN, Rozita M, Rohana AG, Halim AG, Norella K, Phang KS. Subclinical acquired syphilis masquerading as membranous glomerulonephritis. Med. J. Malaysia 61: 484-486 (2006).

• Soerensen H, Schneidewind-Mueller JM, Lange D, Kashiwagi N, Franz M, Yokoyama T, Ramlow W. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol. Int. 26: 409-415 (2006). *

• Song YW, Han CW, Kang SW, Baek HJ, Lee EB, Shin CH, Hahn BH, Tsao BP. Abnormal distribution of Fc gamma receptor type IIa polymorphisms in Korean patients with systemic lupus erythematosus. Arthritis Rheum. 41: 421-426 (1998). *

• Soos TJ, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. Drug News Perspect. 19: 325-328 (2006).

• Soriano E, Fischman D, Cheriyath P. Membranoproliferative glomerulonephritis in patients with cystic fibrosis: coincidence or comorbidity? A case series. South. Med. J. 101: 641-645 (2008).

• Soubassi L, Haidopoulos D, Sindos M, Pilalis A, Chaniotis D, Diakomanolis E, Antsaklis A, Zerefos N. Pregnancy outcome in women with pre-existing lupus nephritis. J. Obstet. Gynaecol. 24: 630-634 (2004).

• Soy M, Pamuk ON, Gerenli M, Celik Y. A primary Sjogren's syndrome patient with distal renal tubular acidosis, who presented with symptoms of hypokalemic periodic paralysis. Report of a case study and review of the literature. Rheumatol. Int. 26: 86-89 (2005). *

• Spangenberg HC, Blum HE. Vasculitis and liver disease. Schweiz. Rundsch. Med. Prax. 95: 1557-1562 (2006).

• Sprovieri SR, Sens YA, Martini Filho D. Association between polymorphisms of the renin-angiotensin system and more severe histological forms of lupus nephritis. Clin. Nephrol. 64: 20-27 (2005).

• Stasikowska O, Danilewicz M, Wagrowska-Danilewicz M. The significant role of RANTES and CCR5 in progressive tubulointerstitial lesions in lupus nephropathy. Pol. J. Pathol. 58: 35-40 (2007).

• Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavvidou F, Zachou K, Koukoulis GK, Dalekos GN. A case of membranous nephropathy associated with Sjoegren syndrome, polymyositis and autoimmune hepatitis. Clin. Nephrol. 70: 245-250 (2008).

• Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 23: 429-448 (2000).

• Stohl W, Jacob N, Quinn WJ 3rd, Cancro MP, Gao H, Putterman C, Gao X, Pricop L, Koss MN. Global T cell dysregulation in mon-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J. Immunol. 181: 833-841 (2008). *

• Stoll ML, Price KD, Silvin CJ, Jiang F, Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWRxNZB)F(1) murine model. J. Autoimmun. 29: 30-37 (2007).

• Su YJ, Lai YC, Chou CY, Chang WH. Ischemic colitis secondary to xanthogranulomatous pyelonephritis. Int. J. Infect. Dis. 13: e89-391 (2009).

• Subramanian S, Yim YS, Liu K, Tus K, Zhou XJ, Wakeland EK. Epistatic suppression of systemic lupus erythematosus: fine mapping of Sles1 to less than 1 mb. J. Immunol. 175: 1062-1072 (2005). *

• Sugimoto K, Fujita S, Yanagida H, Shimada Y, Tabata N, Yagi K, Okada M, Takemura T. Clinical manifestations and analyses of the cytotoxic T-lymphocyte associated-4 gene in two Japanese families with systemic lupus erythematosus. Clin. Exp. Nephrol. 12: 149-154 (2008). *

• Sugimoto K, Yamaji K, Yang KS, Kanai Y, Tsuda H, Hashimoto H. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther. Apher. Dial. 10: 187-192 (2006). *

• Sugimoto T, Koyama T, Kanasaki K, Morita Y, Yokomaku Y, Deji N, Tanaka Y, Uzu T, Kashiwagi A. Anti-neutrophil cytoplasmic antibodies-related necrotising crescentic glomerulonephritis in a patient with rheumatoid arthritis. Nephrology (Carlton) 11: 478 (2006). *

• Sugiyama H, Maruyama M, Morinaga H, Inoue T, Takiue KI, Kikumoto Y, Kinomura M, Sada KE, Akagi S, Kitamura S, Maeshima Y, Makino H. Unique microstructures and podocytic infolding in glomerular basement membrane associated with collagen diseases: a report of three cases. Clin. Exp. Nephrol. 12: 450-454 (2008).

• Sugiyama M, Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Ikoma S, Funauchi M. Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. Clin. Immunol. 128: 103-108 (2008). *

• Sugiyama N, Nakashima H, Yoshimura T, Sadanaga A, Shimizu S, Masutani K, Igawa T, Akahoshi M, Miyake K, Takeda A, Yoshimura A, Hamano S, Yoshida H. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1). Ann. Rheum. Dis. 67: 1461-1467 (2008). *

• Sugiyama T, Oishi Y, Sueishi M, Matsumura R, Tomioka H, Akikusa B. Diffuse proliferative lupus nephritis in a patient with ulcerative colitis. Ryumachi 36: 651-655 (1996).

• Sulikowska B, Czarny J, Rosc D, Odrowaz-Sypniewska G, Manitius J, Sliwka DM. Some metabolic and genetic risk factors and the progression of IgA nephropathy - preliminary report. Pol. Merkur. Lekarski. 21: 132-135 (2006).

• Sun D, Krishnan A, Su J, Lawrence R, Zaman K, Fernandes G. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice. Cell. Immunol. 228: 54-65 (2004). *

• Suresh S, Demirci FY, Jacobs E, Kao AH, Rhew EY, Sanghera DK, Selzer F, Sutton-Tyrrell K, McPherson D, Bontempo FA, Kammerer CM, Ramsey-Goldman R, Manzi S, Kamboh MI. Apolipoprotein H promoter polymorphisms in relation to lupus and lupus-related phenotypes. J. Rheumatol. 36: 315-322 (2009).

• Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcon GS, Kimberly RP, Tomino Y, Mestecky J, Novak J. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J. Clin. Invest. 118: 629-639 (2008). *

• Suzuki H, Sakuma Y, Kanesaki Y, Eiro M, Asahi K, Sanada H, Watanabe K, Katoh T, Watanabe T. Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy. Clin. Nephrol. 62: 173-179 (2004).

• Suzuki K, Imaizumi T, Tsugawa K, Ito E, Tanaka H. Expression of retinoic acid-inducible gene-I in lupus nephritis. Nephrol. Dial. Transplant. 22: 2407-2409 (2007).

• Szczepaniska M, Muszewska E, Szprynger K, Niwinska-Faryna B. Systemic lupus erythematosus and pregnancy. Wiad. Lek. 61: 161-165 (2008).

• Szigeti N, Kovacs T, Degrell P, Fabian G, Wittmann I, Nagy J. Secondary IgA-nephropathy in gastroenterological diseases. Orv. Hetil. 148: 313-318 (2007).

• Tada Y, Koarada S, Tomiyoshi Y, Morito F, Mitamura M, Haruta Y, Ohta A, Nagasawa K. Role of inducible costimulator in the development of lupus in MRL/lpr mice. Clin. Immunol. 120: 179-188 (2006). *

• Tadic M, Grgurevic I, Scukanec-Spoljar M, Bozic B, Marusic S, Horvatic I, Galesic K. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 10: 103-105 (2005).

• Taguma Y, Chiba S, Sato H. Membranoproliferative glomerulonephritis. Nippon Rinsho 62: 1849-1855 (2004).

• Takada K, Suzuki K, Matsumoto M, Okada M, Nakanishi T, Horikoshi H, Higuchi T, Ohsuzu F. Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies. Scand. J. Rheumatol. 37: 360-364 (2008).

• Tanaka A, Kasahara M, Miyawaki T, Yahata K, Hashimoto H, Sugawara A, Ueda S, Matsuo T, Kuwahara T. A case of selective IgM deficiency associated with systemic lupus erythematosus. Nippon Jinzo Gakkai Shi 38: 185-190 (1996).

• Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin. Rheumatol. 27: 85-89 (2008).

• Tanaka T, Tago F, Fang SP, Shimura N, Kojima S. Repeated 0.5-Gy gamma-ray irradiation attenuates autoimmune manifestations in MRL-lpr/lpr mice. Int. J. Radiat. Biol. 81: 731-740 (2005).

• Tang H, Chelamcharla M, Baird BC, Shihab FS, Koford JK, Goldfarb-Rumyantzev AS. Factors affecting kidney-transplant outcome in recipients with lupus nephritis. Clin. Transplant. 22: 263-272 (2008).

• Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton) 10: 174-179 (2005).

• Tao J, Dong J, Li Y, Liu YQ, Yang J, Wu Y, Li L, Shen GX, Tan ZJ, Tu YT. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics. J. Eur. Acad. Dermatol. Venereol. 23: 433-437 (2009).

• Tarasenko T, Kole HK, Bolland S. A lupus-suppressor BALB/c locus restricts IgG2 autoantibodies without altering intrinsic B cell-tolerance mechanisms. J. Immunol. 180: 3807-3814 (2008). *

• Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 16: 324-328 (2007).

• Tarr T, Muzes G, Pitlik E, Lakos G, Csepany T, Soltesz P, Zeher M, Szegedi G, Kiss E. Is the primary antiphospholipid syndrome a forerunner of SLE? Orv. Hetil. 146: 203-207 (2005).

• Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 4: e1000084 (2008). *

• Tchorbanov AI, Voynova EN, Mihaylova NM, Todorov TA, Nikolova M, Yomtova VM, Chiang BL, Vassilev TL. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 37: 3587-3596 (2007). *

• Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA. Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood 111: 705-714 (2008). *

• Tee JB, Reznik V, Krous HF. Overlapping presentation of fungal tubulointerstitial nephritis in an immunosuppressed pediatric patient. Pediatr. Nephrol. 24: 1573-1575 (2009).

• Tekin F, Ozutemiz O, Ilter T. Acute tubulointerstitial nephritis due to 5-aminosalicylic acid in a patient with ulcerative colitis and chronic renal failure. Turk. J. Gastroenterol. 17: 153-154 (2006). *

• Thonhofer R, Soleiman A, Kriessmayr M, Thonhofer U, Wipfler E, Gaugg M, Eder S, Erlacher L. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy. Scand. J. Rheumatol. 35: 485-488 (2006).

• Thorburn CM, Prokunina-Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon-Riquelme ME, Criswell LA. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun. 8: 279-287 (2007). *

• Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 35: 1493-1496 (1994). *

• Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM; Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin. Infect. Dis. 37: 905-911 (2003). *

• Ting SM, Toth T, Caskey F. alpha1-Antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: is renal involvement caused by A1AT deposition? Clin. Nephrol. 70: 159-162 (2008).

• Tiple A, Kamar N, Esposito L, Mengelle C, Combelles S, Otal P, Celine Guilbeau-Frugier C, Rostaing L. Unusual presentation of cytomegalovirus infection in patients after organ transplant. Exp. Clin. Transplant. 7: 45-49 (2009). *

• Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin. Exp. Immunol. 142: 207-215 (2005). *

• Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol. 66: 395-402 (2005).

• Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37: 457-464 (2004).

• Traynor A, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology (Oxford) 38: 767-772 (1999). *

• Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin. Immunopathol. 27: 276-285 (2005). *

• Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, Tesar V, Sadallah S, Schifferli J. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol. Dial. Transplant. 21: 3115-3121 (2006).

• Trimarchi HM, Iotti A, Iotti R, Freixas EA, Peters R. Immunoglobulin A nephropathy and ulcerative colitis. A focus on their pathogenesis. Am. J. Nephrol. 21: 400-405 (2001).

• Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, Bontempo F, Kammerer C, Kamboh MI. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum. 54: 1928-1939 (2006). *

• Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin. Biol. Ther. 5: 243-251 (2005).

• Trouw LA, Seelen MA, Duijs JM, Wagner S, Loos M, Bajema IM, van Kooten C, Roos A, Daha MR. Activation of the lectin pathway in murine lupus nephritis. Mol. Immunol. 42: 731-740 (2005). *

• Tsai TC, Chen CY, Lin WT, Lee WJ, Chen HC. Sjogren's syndrome complicated with IgA nephropathy and leukocytoclastic vasculitis. Ren. Fail. 30: 755-758 (2008).

• Tsao BP. Update on human systemic lupus erythematosus genetics. Curr. Opin. Rheumatol. 16: 513-521 (2004).

• Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, Wallace DJ, Kitridou RC, Chen SL, Shen N, Song YW, Isenberg DA, Yu CL, Hahn BH, Rotter JI. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J. Clin. Invest. 99: 725-731 (1997). *

• Tsao BP, Grossman JM. Genetics and systemic lupus erythematosus. Curr. Rheumatol. Rep. 3: 183-190 (2001).

• Tse WY, Abadeh S, McTiernan A, Jefferis R, Savage CO, Adu D. No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin. Exp. Immunol. 117: 198-205 (1999). *

• Tseng JC, Lu LY, Hu RJ, Kau CK, Cheng HH, Lin PR, Sun CW, Liang HT, Lam HC, Tai MH. Elevated serum anti-endothelial cell autoantibodies titer is associated with lupus nephritis in patients with systemic lupus erythematosus. J. Microbiol. Immunol. Infect. 40: 50-55 (2007). *

• Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28: 833-846 (2008). *

• Tsuchiya N, Kawasaki A, Tsao BP, Komata T, Grossman JM, Tokunaga K. Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun. 2: 317-322 (2001). *

• Tsuda T, Moriguchi M, Asanuma Y, Imamura S, Toyoda A, Yamada S, Terai C, Suzuki K, Tabei K. C4B deficiency associated with membranoproliferative glomerulonephritis. Intern. Med. 46: 765-770 (2007). *

• Tsugawa K, Oki E, Suzuki K, Imaizumi T, Ito E, Tanaka H. Expression of mRNA for functional molecules in urinary sediment in glomerulonephritis. Pediatr. Nephrol. 23: 395-401 (2008).

• Tsuji F, Yoshimi M, Katsuta O, Takai M, Ishihara K, Aono H. Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice. BMC Musculoskelet. Disord. 10: 23 (2009). *

• Tsujimura S, Saito K, Tokunaga M, Nakatsuka K, Nakayamada S, Nakano K, Tanaka Y. Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod. Rheumatol. 15: 28-32 (2005).

• Tsukamoto H, Horiuchi T. Clinical aspects of the complement system. Rinsho Byori 54: 757-762 (2006).

• Tsuneyama K, Nose M, Nisihara M, Katayanagi K, Harada K, Nakanuma Y. Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/lpr mice: possible animal model for primary biliary cirrhosis. Pathol. Int. 51: 418-424 (2001). *

• Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, Richards HB. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 50: 1842-1849 (2004). *

• Tucker RM, Roark CL, Santiago-Raber ML, Izui S, Kotzin BL. Association between nuclear antigens and endogenous retrovirus in the generation of autoantibody responses in murine lupus. Arthritis Rheum. 50: 3626-3636 (2004). *

• Turkcapar N, Olmez U, Ozer D, Duzgun N, Duman M. A case of overlap syndrome with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and secondary Sjogren's syndrome. Rheumatol. Int. 26: 841-845 (2006). *

• Turkcapar N, Ozyuncu N, Cinar K, Ensari A, Kucuk O, Idilman R, Duman N, Ozden A. A case of systemic lupus erythematosus presenting with protein-losing enteropathy. Turk. J. Gastroenterol. 17: 226-230 (2006). *

• Tzioufas AG, Voulgarelis M. Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract. Res. Clin. Rheumatol. 21: 989-1010 (2007).

• Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Fukata M, Miyoshi H, Sakaguchi Y, Fukui T, Matsushita M, Takaoka M, Okazaki K. Long-term outcome of autoimmune pancreatitis. J. Gastroenterol. Apr 25 [Epub ahead of print] (2009). *

• Uchiyama-Tanaka Y, Mori Y, Kimura T, Sonomura K, Umemura S, Kishimoto N, Nose A, Tokoro T, Kijima Y, Yamahara H, Nagata T, Masaki H, Umeda Y, Okazaki K, Iwasaka T. Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis. Am. J. Kidney Dis. 43: e18-e25 (2004).

• Uhm WS, Lee HS, Chung YH, Kim TH, Bae SC, Joo KB, Kim TY, Yoo DH. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus 11: 227-233 (2002).

• Ulinski T, Perrin L, Morris M, Houang M, Cabrol S, Grapin C, Chabbert-Buffet N, Bensman A, Deschenes G, Giurgea I. APECED syndrome with renal failure: impact of post transplant immunosuppression on disease activity. J. Clin. Endocrinol. Metab. 91: 192-195 (2006). *

• Unal A, Sipahioglu MH, Akgun H, Yurci A, Tokgoz B, Erkilic K, Oymak O, Utas C. Crohn's disease complicated by granulomatous interstitial nephritis, choroidal neovascularization, and central retinal vein occlusion. Intern. Med. 47: 103-107 (2008). *

• Urnovitz HB, Murphy WH. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev. 9: 72-99 (1996). *

• Urschel S, Kayikci L, Wintergerst U, Notheis G, Jansson A, Belohradsky BH. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J. Pediatr. 154: 888-894 (2009).

• Uslu N, Demir H, Saltik-Temizel IN, Topaloglu R, Gurakan F, Yuce A. Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig. Dis. Sci. 52: 2926-2929 (2007). *

• Uthman I. Pharmacological therapy of vasculitis: an update. Curr. Opin. Pharmacol. 4: 177-182 (2004).

• Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, Garini G, Manganelli P, Bottero P, Tumiati B, Sinico RA, Savi M, Buzio C, Neri TM; Secondary and Primary Vasculitis Study Group. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 56: 3159-3166 (2007). *

• van Bavel CC, van der Vlag J, Berden JH. Glomerular binding of anti-dsDNA autoantibodies: the dispute resolved? Kidney Int. 71: 600-601 (2007). *

• Van Biervliet S, Raes A, Vande Walle J, Van Winckel M, Robberecht E, Praet M. Mesalazine interstitial nephritis presenting as colitis ulcerosa exacerbation. Acta Gastroenterol. Belg. 69: 321-322 (2006).

• Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).

• Van Rappard-Van Der Veen FM, Radaszkiewicz T, Terraneo L, Gleichmann E. Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice. J. Immunol. 130: 2693-2701 (1983).

• Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126: 1733-1739 (2004). *

• van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8: 181-187 (1999).

• Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18: 913-922 (2007). *

• Vazgiourakis V, Sidiropoulos P, Bertsias G, Koutsounaki E, Fragouli E, Raptopoulou A, Kritikos H, Boumpas DT, Goulielmos GN. Association of the nitric oxide synthase (eNOS) gene polymorphism with increased risk for both lupus glomerulonephritis and rheumatoid arthritis in a single genetically homogeneous population. Lupus 16: 867-874 (2007).

• Veelken R, Vogel EM, Hilgers K, Amann K, Hartner A, Sass G, Neuhuber W, Tiegs G. Autonomic renal denervation ameliorates experimental glomerulonephritis. J. Am. Soc. Nephrol. 19: 1371-1478 (2008).

• Velazquez-Cruz R, Orozco L, Espinosa-Rosales F, Carreno-Manjarrez R, Solis-Vallejo E, Lopez-Lara ND, Ruiz-Lopez IK, Rodriguez-Lozano AL, Estrada-Gil JK, Jimenez-Sanchez G, Baca V. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur. J. Hum. Genet. 15: 336-341 (2007). *

• Verhagen AM, Wallace ME, Goradia A, Jones SA, Croom HA, Metcalf D, Collinge JE, Maxwell MJ, Hibbs ML, Alexander WS, Hilton DJ, Kile BT, Starr R. A kinase-dead allele of Lyn attenuates autoimmune disease normally associated with Lyn deficiency. J. Immunol. 182: 2020-2029 (2009).

• Verzijl JM, van Bodegraven AA. Mesalazine - still a first-line therapy. European Pharmacotherapy, Business Briefing (http://bbriefings.com/pdf/26/ept032_r_26_verzil.pdf), pp. 1-7 (2003). *

• Viallard JF, Bonnet S, Couzi L, Deminiere C, Miossec V, Mercie P, Aparicio M, Pellegrin JL. Glomerulonephritis caused by Actinobacillus actinomycetemcomitans mimicking c-ANCA-positive vasculitis. Nephrol. Dial. Transplant. 17: 663-665 (2002). *

• Viau M, Zouali M. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F(1) mice. Mol. Immunol. 42: 849-855 (2005). *

• Vielhauer V, Anders HJ. Blockade of chemokine-mediated tissue injury in lupus nephritis. Endocr. Metab. Immune Disord. Drug Targets 6: 313-321 (2006).

• Vielhauer V, Anders HJ, Schlondorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin. Nephrol. 27: 81-97 (2007).

• Vielhauer V, Mayadas TN. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin. Nephrol. 27: 286-308 (2007).

• Vigani AG, Macedo-de-Oliveira A, Pavan MH, Pedro MN, Goncales Jr FL. Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report. Braz. J. Med. Biol. Res. 38: 1729-1734 (2005). *

• Vijayalakshmi AM, Jayavardhana A. Bullous systemic lupus erythematosus and lupus nephritis in a 10 year old boy. Indian Pediatr. 44: 861-863 (2007). *

• Vizjak A, Nagode B, Rott T, Koselj M, Rozman B, Kaplan-Pavlovcic S, Kosnik M, Petric V, Ferluga D. Antineutrophil cytoplasmic autoantibodies-antigen specificity and associated diseases. Wien. Klin. Wochenschr. 112: 665-670 (2000).

• Vlassopoulos D, Divari E, Savva S, Nakopoulou L, Tziallas M, Kokka H, Oeconomopoulos P, Hadjiconstantinou V. Membranous glomerulonephritis associated with primary biliary cirrhosis. Nephrol. Dial. Transplant. 13: 459-461 (1998).

• Vojtova L, Zima T, Tesar V, Kazderova M. Study of urinary proteomes in patients with nephrotic syndrome. Folia. Biol. (Praha.) 53: 58-65 (2007).

• von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86: 875-879 (2008).

• von Vietinghoff S, Busjahn A, Schonemann C, Massenkeil G, Otto B, Luft FC, Kettritz R. Major histocompatibility complex HLA region largely explains the genetic variance exercised on neutrophil membrane proteinase 3 expression. J. Am. Soc. Nephrol. 17: 3185-3191 (2006). *

• Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjogren's syndrome. Clin. Exp. Rheumatol. 26: S66-S71 (2008).

• Vuckovic B, Ilic T, Mitic I, Knezevic V, Vodopivec S, Curic S. Goodpasture's syndrome - case report. Med. Pregl. 57: 391-395 (2004).

• Vuotila M, Ikaheimo R, Pietilainen T. Interstitial nephritis associated with mesalazine therapy. Duodecim. 119: 1978-1982 (2003).

• Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu. Rev. Immunol. 16: 261-292 (1998). *

• Wada K, Shinoda T, Yoshimoto H. A case report of autoimmune pancreatitis accompanied with rapidly developing hyperglycemia and hypertension in a chronic hemodialysis patient. Ther. Apher. Dial. 11: 150-154 (2007). *

• Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 70: 1403-1412 (2006). *

• Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 178: 271-279 (2007). *

• Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou XJ, Batteux F, Wong D, Wakeland EK, Mohan C. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J. Immunol. 182: 4448-4458 (2009).

• Wang XF, Yuan SL, Jiang L, Zhang XL, Li SF, Guo Y, Wu CL, Chen JJ. Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23: 1041-1042 (2007).

• Wang Y, Qiao B, Wang Y, Han X, Chu Y, Xiong S. Autoantibodies closely relate to the elevation level of in vivo hydrogen peroxide and tissue damage in systemic lupus erythematosus. DNA Cell Biol. 25: 563-570 (2006).

• Wang Z, Zhang B, Yang L, Ding J, Ding HF. Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J. Biol. Chem. 283: 10698-10706 (2008). *

• Wardle EN. PPAR: receptors that regulate inflammation. Saudi J. Kidney Dis. Transpl. 15: 1-6 (2004). *

• Wasilewska A, Zoch-Zwierz WM, Tenderenda E, Szynaka B. IgA nephropathy in a girl with psoriasis and seronegative arthritis. Pediatr. Dermatol. 25: 408-409 (2008).

• Watanabe N, Takabayashi K. Recent investigations on the basis of pathogenesis of SLE and new therapeutic approaches. Nippon Rinsho 67: 500-505 (2009).

• Waters A, Langlois V, Thorner P, Geary D. Atypical p-ANCA is not a poor prognostic marker in postinfectious glomerulonephritis. Pediatr. Nephrol. 22: 1383-1386 (2007).

• Waters AM, Zachos M, Herzenberg AM, Harvey E, Rosenblum ND. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease. Nat. Clin. Pract. Nephrol. 4: 693-697 (2008).

• Watson SJ, Jenkins DA, Bellamy CO. Nephropathy in IgG4-related systemic disease. Am. J. Surg. Pathol. 30: 1472-1477 (2006).

• Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178: 6624-6633 (2007). *

• Welch TR, Beischel L, Balakrishnan K, Quinlan M, West CD. Major-histocompatibility-complex extended haplotypes in membranoproliferative glomerulonephritis. N. Engl. J. Med. 314: 1476-1481 (1986).

• Wen X, Zhang D, Kikuchi Y, Jiang Y, Nakamura K, Xiu Y, Tsurui H, Takahashi K, Abe M, Ohtsuji M, Nishimura H, Takatsu K, Shirai T, Hirose S. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur. J. Immunol. 34: 2740 (2004). *

• Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD. DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46: 1796-1803 (2007). *

• Wenderfer SE, Soimo K, Wetsel RA, Braun MC. Analysis of C4 and the C4 binding protein in the MRL/lpr mouse. Arthritis Res. Ther. 9: R114 (2007). *

• Wenderfer SE, Wang H, Ke B, Wetsel RA, Braun MC. C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol. Immunol. 46: 1397-1404 (2009). *

• Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization. Am. J. Gastroenterol. 102: 1429-1435 (2007). *

• Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann. Rheum. Dis. 67: 154-161 (2008).

• Wilcox GM, Aretz HT, Roy MA, Roche JK. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 98: 786-791 (1990).

• Wither J, Vukusic B. Autoimmunity develops in lupus-prone NZB mice despite normal T cell tolerance. J. Immunol. 161: 4555-4562 (1998). *

• Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron. 67: 481-482 (1994).

• Woo KT, Chan CM, Choong HL, Tan HK, Foo M, Lee EJ, Tan CC, Lee GS, Tan SH, Vathsala A, Lim CH, Chiang GS, Fook-Chong S, Yi Z, Tan HB, Wong KS. High dose losartan and ACE gene polymorphism in IgA nephritis. Genomic Med. 2: 83-91 (2008). *

• Woo KT, Lau YK, Zhao Y, Liu FE, Tan HB, Tan EK, Stephanie FC, Chan CM, Wong KS. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis. Cell. Mol. Immunol. 4: 227-232 (2007). *

• World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol. Dial. Transplant. 11: 614-621 (1996).

• Wornle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M, Blattner S, Bock E, Kretzler M, Grone HJ, Schlondorff D. Novel role of Toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am. J. Pathol. 168: 370-385 (2006). *

• Wu H, Center E, Tsokos G, Weiner H. Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 18: 586-596 (2009).

• Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+CD25-LAP+ regulatory T cell and is associated with down-regulation of IL-17+CD4+ICOS+CXCR5+ follicular helper T cells. J. Immunol. 181: 6038-6050 (2008).

• Wu J, Chen L, Zhang D, Huo M, Zhang X, Pu D, Guan Y. Peroxisome proliferator-activated receptors and renal diseases. Front. Biosci. 14: 995-1009 (2009).

• Wu Q, Koike Y, Nishina M, Toyoda M, Suzuki D, Endoh M. A case with membranous lupus nephritis developing after a twenty-year remission of membranoproliferative glomerulonephritis. Intern. Med. 45: 531-536 (2006). *

• Wu T, Mohan C. Three pathogenic determinants in immune nephritis-anti-glomerular antibody specificity, innate triggers and host genetics. Front. Biosci. 12: 2207-2211 (2007).

• Xiao ZY, Zhou WX, Zhang YX, Cheng JP, He JF, Yang RF, Yun LH. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production. Life Sci. 81: 1403-1410 (2007). *

• Xie HF, Feng H, Zeng HY, Li J, Shi W, Yi M, Wu B. Establishment of systemic lupus erythematosus-like murine model with Sm mimotope. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29: 191-195 (2007).

• Xie S, Li L, Chang S, Sharma R, Kaliyaperumal A, Datta SK, Mohan C. Genetic origin of lupus in NZB/SWR hybrids: lessons from an intercross study. Arthritis Rheum. 52: 659-667 (2005). *

• Xu H, Kurihara H, Ito T, Kikuchi H, Yoshida K, Yamanokuchi H, Asari A. The keratan sulfate disaccharide gal(6S03) b1,4 glcNAc(6S03) modulates IL12 production by macrophages in murine Thy-1 type autoimmune disease. J. Biol. Chem. 280: 20879-20886 (2005). *

• Xu Z, Duan B, Croker BP, Morel L. STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus. Clin. Immunol. 120: 189-198 (2006). *

• Xu Z, Duan B, Croker BP, Wakeland EK, Morel L. Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J. Immunol. 175: 936-943 (2005). *

• Yahiaoui Y, Jablonski M, Hubert D, Mosnier-Pudar H, Noel LH, Stern M, Grenet D, Grunfeld JP, Chauveau D, Fakhouri F. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin. J. Am. Soc. Nephrol. 4: 921-928 (2009).

• Yamamoto M, Takahashi H, Naishiro Y, Isshiki H, Ohara M, Suzuki C, Yamamoto H, Kokai Y, Himi T, Imai K, Shinomura Y. Mikulicz's disease and systemic IgG4-related plasmacytic syndrome (SIPS). Nihon Rinsho Meneki Gakkai Kaishi 31: 1-8 (2008). *

• Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Shinomura Y, Imai K. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod. Rheumatol. 16: 335-340 (2006). *

• Yamasaki S, Origuchi T, Nakata K, Toriyama K, Taguchi T, Ida H, Kawakami A, Eguchi K. Autoimmune hepatitis in a patient with systemic lupus erythematosus: a case report. Mod. Rheumatol. 14: 169-173 (2004).

• Yamashita K, Yorioka N, Kyuden Y, Naito T, Tanji C, Ueda C, Usui K, Shigemoto K, Harada S, Yamakido M. A case of CREST syndrome and myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin. Nephrol. 53: 296-300 (2000).

• Yamauchi M, Hashimoto M, Ichiyama K, Yoshida R, Hanada T, Muta T, Komune S, Kobayashi T, Yoshimura A. Ifi202, an IFN-inducible candidate gene for lupus susceptibility in NZB/W F1 mice, is a positive regulator for NF-kappaB activation in dendritic cells. Int. Immunol. 19: 935-942 (2007). *

• Yamazaki-Nakashimada M, Zaltzman-Girshevich S, Garcia de la Puente S, De Leon-Bojorge B, Espinosa-Padilla S, Saez-de-Ocariz M, Carrasco-Daza D, Hernandez-Bautista V, Perez-Fernandez L, Espinosa-Rosales F. Hyper-IgE syndrome and autoimmunity in Mexican children. Pediatr. Nephrol. 21: 1200-1205 (2006). *

• Yang CW, Hung CC, Wu MS, Tian YC, Chang CT, Pan MJ, Vandewalle A. Toll-like receptor 2 mediates early inflammation by leptospiral outer membrane proteins in proximal tubule cells. Kidney Int. 69: 815-822 (2006). *

• Yang JJ, Tuttle R, Falk RJ, Jennette JC. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease. Clin. Exp. Immunol. 105: 125-131 (1996). *

• Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, Van Kaer L, Singh RR. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum. 56: 1219-1233 (2007). *

• Yang Y, Lhotta K, Chung EK, Eder P, Neumair F, Yu CY. Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus. J. Immunol. 173: 2803-2814 (2004). *

• Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28: 313-314 (2001). *

• Yoneda K, Murata K, Katayama K, Ishikawa E, Fuke H, Yamamoto N, Ito K, Shiraki K, Nomura S. Tubulointerstitial nephritis associated with IgG4-related autoimmune disease. Am. J. Kidney Dis. 50: 455-462 (2007).

• Youm JY, Lee OY, Park MH, Yang SY, Han SH, Baek YH, Park SR, Lee HL, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH, Kee CS. Crohn's disease associated with IgA nephropathy. Korean J. Gastroenterol. 47: 324-328 (2006).

• Yu YW, Liu ZR, Xie D, Chen SX, Li HY. Clinical significance of antineutrophil cytoplasmic antibodies in patients with lupus nephritis. Nan Fang Yi Ke Da Xue Xue Bao 26: 833-836 (2006).

• Yun HR, Koh HK, Kim SS, Chung WT, Kim DW, Hong KP, Song GG, Chang HK, Choe JY, Bae SC, Salmon JE, Yoo DH, Kim TY, Kim SY. FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients. Lupus 10: 466-472 (2001).

• Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J. Immunol. 154: 3025-3035 (1995).

• Zabaleta-Lanz ME, Munoz LE, Tapanes FJ, Vargas-Arenas RE, Daboin I, Barrios Y, Pinto JA, Bianco NE. Further description of early clinically silent lupus nephritis. Lupus 15: 845-851 (2006).

• Zaffanello M, Brugnara M, Franchini M. Therapy for children with Henoch-Schonlein purpura nephritis: a systematic review. ScientificWorldJournal 7: 20-30 (2007).

• Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 29: 219-228 (2005).

• Zandman-Goddard G, Shoenfeld Y. Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14 Suppl. 1: s12-s16 (2005).

• Zeller GC, Hirahashi J, Schwarting A, Sharpe AH, Kelley VR. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus. J. Am. Soc. Nephrol. 17: 122-130 (2006). *

• Zhang D, Fujio K, Jiang Y, Zhao J, Tada N, Sudo K, Tsurui H, Nakamura K, Yamamoto K, Nishimura H, Shirai T, Hirose S. Dissection of the role of MHC class II A and E genes in autoimmune susceptibility in murine lupus models with intragenic recombination. Proc. Natl. Acad. Sci. U.S.A. 101: 13838-13843 (2004). *

• Zhang J, Ai R, Chow F. The polymorphisms of HLA-DR and TNF B loci in northern Chinese Han nationality and susceptibility to systemic lupus erythematosus. Chin. Med. Sci. J. 12: 107-110 (1997).

• Zhang J, Chen Y, Li J, Zhang R, Wu Y, Zou L, Zhao T, Zhang X, Han J, Chen A, Wu Y. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J. Nephrol. 19: 429-438 (2006).

• Zhang J, Zhou F, Ai R. Study on some susceptible genes of systemic lupus erythematosus in Han nationality of China. Zhonghua Nei Ke Za Zhi 35: 19-22 (1996).

• Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 56: 4132-4141 (2007). *

• Zhang Y, Su SC, Hecox DB, Brady GF, Mackin KM, Clark AG, Foster MH. Central tolerance regulates B cells reactive with Goodpasture antigen alpha3(IV)NC1 collagen. J. Immunol. 181: 6092-6100 (2008).

• Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, Li LH, Chen GP, Ye DQ. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. Apr 4 [Epub ahead of print] (2009). *

• Zhao Z, Weinstein E, Tuzova M, Davidson A, Mundel P, Marambio P, Putterman C. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum. 52: 522-530 (2005). *

• Zheng L, Sinniah R, Hsu SI. Pathogenic role of NF-kappaB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J. Histochem. Cytochem. 56: 517-529 (2008). *

• Zheng L, Sinniah R, I-Hong Hsu S. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum. Pathol. 37: 637-647 (2006).

• Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant. 22: 1933-1942 (2007).

• Zhu B, Symonds AL, Martin JE, Kioussis D, Wraith DC, Li S, Wang P. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupus-like autoimmune disease. J. Exp. Med. 205: 2295-2307 (2008). *

• Zhu L, Yang X, Ji Y, Chen W, Guan W, Zhou S, Yu X. Up-regulated renal expression of TNF-alpha signalling adapter proteins in lupus glomerulonephritis. Lupus 18: 116-127 (2009).

• Zhu LJ, Liu ZH, Zeng CH, Chen ZH, Yu C, Li LS. Association of interleukin-10 gene -592 A/C polymorphism with the clinical and pathological diversity of lupus nephritis. Clin. Exp. Rheumatol. 23: 854-860 (2005).

• Zipfel PF, Hallstrom T, Hammerschmidt S, Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 26 Suppl. 8: I67-I74 (2008).

• Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, Remuzzi G, Benigni A. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum. 56: 1629-1637 (2007). *

• Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70: 97-103 (2006). *

• Zykova SN, Seredkina N, Benjaminsen J, Rekvig OP. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice. Arthritis Rheum. 58: 813-825 (2008). *

Number of references = 1017

www psc-literature.org